<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art560.dtd?><?SourceDTD.Version 5.6.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_HLY6408 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEgr7 jpg ?><?FILEgr8 jpg ?><?FILEgr9 jpg ?><?FILEgr10 jpg ?><?FILEgr11 jpg ?><?FILEgr12 jpg ?><?FILEgr13 jpg ?><?FILEgr14 jpg ?><?FILEgr15 jpg ?><?FILEgr16 jpg ?><?FILEgr17 jpg ?><?FILEgr18 jpg ?><?FILEgr19 jpg ?><?FILEgr20 jpg ?><?FILEmmc1 xlsx ?><?FILEmmc2 xlsx ?><?FILEmmc3 xlsx ?><?FILEmmc4 xlsx ?><?FILEmmc5 xlsx ?><?FILEmmc6 xlsx ?><?FILEmmc7 xlsx ?><?FILEmmc8 xlsx ?><?FILEmmc9 xlsx ?><?FILEsi1 svg ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Heliyon</journal-id><journal-id journal-id-type="iso-abbrev">Heliyon</journal-id><journal-title-group><journal-title>Heliyon</journal-title></journal-title-group><issn pub-type="epub">2405-8440</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7970325</article-id><article-id pub-id-type="pii">S2405-8440(21)00513-2</article-id><article-id pub-id-type="doi">10.1016/j.heliyon.2021.e06408</article-id><article-id pub-id-type="publisher-id">e06408</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Vladimirova</surname><given-names>Uliana</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Rumiantsev</surname><given-names>Pavel</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Zolotovskaia</surname><given-names>Marianna</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Albert</surname><given-names>Eugene</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Abrosimov</surname><given-names>Aleksander</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Slashchuk</surname><given-names>Konstantin</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Nikiforovich</surname><given-names>Petr</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Chukhacheva</surname><given-names>Olga</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Gaifullin</surname><given-names>Nurshat</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Suntsova</surname><given-names>Maria</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Zakharova</surname><given-names>Galina</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Glusker</surname><given-names>Alexander</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Nikitin</surname><given-names>Daniil</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au14"><name><surname>Garazha</surname><given-names>Andrew</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au15"><name><surname>Li</surname><given-names>Xinmin</given-names></name><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au16"><name><surname>Kamashev</surname><given-names>Dmitriy</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au17"><name><surname>Drobyshev</surname><given-names>Alexei</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au18"><name><surname>Kochergina-Nikitskaya</surname><given-names>Irina</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au19"><name><surname>Sorokin</surname><given-names>Maxim</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au20"><name><surname>Buzdin</surname><given-names>Anton</given-names></name><email>buzdin@oncobox.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff7" ref-type="aff">g</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>a</label>I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russia</aff><aff id="aff2"><label>b</label>Endocrinology Research Centre, Moscow, 117312, Russia</aff><aff id="aff3"><label>c</label>Omicsway Corp., Walnut, CA, 91789, USA</aff><aff id="aff4"><label>d</label>Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, 141701, Russia</aff><aff id="aff5"><label>e</label>Pirogov Russian National Research Medical University, Moscow, 117997, Russia</aff><aff id="aff6"><label>f</label>Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, 119992, Russia</aff><aff id="aff7"><label>g</label>Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997, Russia</aff><aff id="aff8"><label>h</label>Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, 90095, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. <email>buzdin@oncobox.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>13</day><month>3</month><year>2021</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>3</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>13</day><month>3</month><year>2021</year></pub-date><volume>7</volume><issue>3</issue><elocation-id>e06408</elocation-id><history><date date-type="received"><day>4</day><month>9</month><year>2020</year></date><date date-type="rev-recd"><day>22</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 The Author(s)</copyright-statement><copyright-year>2021</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>DNA repair can prevent mutations and cancer development, but it can also restore damaged tumor cells after chemo and radiation therapy. We performed RNA sequencing on 95 human pathological thyroid biosamples including 17 follicular adenomas, 23 follicular cancers, 3 medullar cancers, 51 papillary cancers and 1 poorly differentiated cancer. The gene expression profiles are annotated here with the clinical and histological diagnoses and, for papillary cancers, with <italic>BRAF</italic> gene V600E mutation status. DNA repair molecular pathway analysis showed strongly upregulated pathway activation levels for most of the differential pathways in the papillary cancer and moderately upregulated pattern in the follicular cancer, when compared to the follicular adenomas. This was observed for the BRCA1, ATM, p53, excision repair, and mismatch repair pathways. This finding was validated using independent thyroid tumor expression dataset PRJEB11591. We also analyzed gene expression patterns linked with the radioiodine resistant thyroid tumors (n = 13) and identified 871 differential genes that according to Gene Ontology analysis formed two functional groups: (i) response to topologically incorrect protein and (ii) aldo-keto reductase (NADP) activity. We also found RNA sequencing reads for two hybrid transcripts: one in-frame fusion for well-known <italic>NCOA4-RET</italic> translocation, and another frameshift fusion of <italic>ALK</italic> oncogene with a new partner <italic>ARHGAP12</italic>. The latter could probably support increased expression of truncated <italic>ALK</italic> downstream from 4<sup>th</sup> exon out of 28. Both fusions were found in papillary thyroid cancers of follicular histologic subtype with node metastases, one of them (<italic>NCOA4-RET</italic>) for the radioactive iodine resistant tumor. The differences in DNA repair activation patterns may help to improve therapy of different thyroid cancer types under investigation and the data communicated may serve for finding additional markers of radioiodine resistance.</p></abstract><abstract abstract-type="teaser" id="abs0015"><p>DNA repair, follicular thyroid adenoma, RNA sequencing, thyroid cancer, personalized medicine, molecular biomarkers, molecular pathway analysis, radiation iodine therapy resistance, papillary thyroid cancer, systems biology.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>DNA repair</kwd><kwd>Follicular thyroid adenoma</kwd><kwd>RNA sequencing</kwd><kwd>Thyroid cancer</kwd><kwd>Personalized medicine</kwd><kwd>Molecular biomarkers</kwd><kwd>Molecular pathway analysis</kwd><kwd>Radiation iodine therapy resistance</kwd><kwd>Papillary thyroid cancer</kwd><kwd>Systems biology</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">About 300 000 new cases of thyroid cancer are recorded globally each year [<xref rid="bib1" ref-type="bibr">1</xref>]. Thyroid cancer is also the fifth most common cancer in women [<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>], and it can move to the fourth place during the next decade [<xref rid="bib3" ref-type="bibr">3</xref>]. Thyroid cancer is a common term for several heterogenous malignancies of thyroid gland, and its clinical manifestation, treatment and prognosis are generally defined by specific tumor subtypes. There are three main types of cells from which thyroid cancers are derived: follicular thyroid cells, Hurthle cells, and parafollicular C cells [<xref rid="bib4" ref-type="bibr">4</xref>]. The most common subtypes of thyroid cancer are follicular thyroid cell-derived tumors, including papillary thyroid cancer (PC), follicular thyroid cancer (FC), and poorly differentiated thyroid cancer [<xref rid="bib5" ref-type="bibr">5</xref>]. In addition, a small proportion of thyroid malignancies belongs to parafollicular C cell-derived medullary thyroid cancer (MC) [<xref rid="bib6" ref-type="bibr">6</xref>]. Molecular characterization of thyroid cancer subtypes can partially solve the problem of understanding specific carcinogenesis mechanisms and selecting appropriate treatments.</p><p id="p0015">In addition, resistance of recurrent thyroid cancers to radioactive iodine treatment, confirmed by observations, poses another challenge for early diagnostics of tumors prone not to respond to the standard therapy regimens [<xref rid="bib7" ref-type="bibr">7</xref>]. Such diagnostics could be used to individually tune treatments, e.g. by adjusting dosage of therapeutic agents and timeline of treatment [<xref rid="bib8" ref-type="bibr">8</xref>]. Two decades ago, a connection between thyroid cancer radioactive iodine resistance and activity of sodium iodide symporter gene <italic>SLC5A5</italic> was discovered [<xref rid="bib9" ref-type="bibr">9</xref>]. Also, <italic>BRAF</italic> and <italic>TERT</italic> mutations were found as the predictors of radio iodine refractory thyroid cancer, especially in duet [<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>]. However, it is clear that the problem has not been solved yet as there are no effective instruments in clinics to predict thyroid cancer resistance to radiation therapy [<xref rid="bib13" ref-type="bibr">13</xref>].</p><p id="p0020">DNA damage is one of the major causes that trigger the development of tumors [<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>]. However, it also is an important focus in chemo and radiation therapy [<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>]. DNA repair mechanisms restore damaged DNA and may have a dual effect on the tumor: they prevent new somatic mutations and may restrict tumor development, but they also restore tumor cells with damaged DNA after chemo and radiation therapy [<xref rid="bib19" ref-type="bibr">19</xref>]. Thus, when planning the chemo and/or radiation therapy, the possibility of DNA repair must be taken into account [<xref rid="bib20" ref-type="bibr">20</xref>]. Low activities of DNA repair genes can make tumor cells more sensitive to the therapy, but at the same time not-repaired damaged tumor cells can form more new clones of treatment resistant cells [<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>]. High activities of certain DNA repair genes, however, can counteract therapy of tumors [<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>]. Therefore, the selection of relevant therapy should ideally be based on the state of DNA repair in an individual tumor. Recently, defects in DNA repair were shown to play an important role in the clonal evolution of thyroid cancer [<xref rid="bib24" ref-type="bibr">24</xref>]. Currently, the thyroid cancer subtypes need more detailed characterization in terms of molecular aspects of DNA repair. This is probably due to the apparent shortage of publicly available gene expression data associated with histological diagnoses of thyroid tumors [<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>].</p><p id="p0025">RNA sequencing is currently a method of choice for generating cancer gene expression data [<xref rid="bib28" ref-type="bibr">28</xref>]. The Genomic Data Commons portal at National Cancer Institute (GDC) [<xref rid="bib29" ref-type="bibr">29</xref>] provides limited access to 502 RNA sequencing profiles of thyroid cancer samples (accessed at June 30, 2020). Nevertheless, GDC dataset can be used for only a limited number of applications because it contains data for only papillary histotype of thyroid cancer (PC) and does not provide immediate open access to raw reads, thus complicating data analysis and limiting its usefulness.</p><p id="p0030">Therefore, more open-access collections of clinically annotated profiles are needed for different types of malignant and benign thyroid tumors and their histotypes, that would be compatible with the reference data for healthy thyroid tissues.</p><p id="p0035">Here we present the subtype-specific characteristic of DNA repair pathway activation in human thyroid tumors. We performed RNA sequencing on 95 human pathological thyroid biosamples including 17 follicular adenomas, 23 follicular cancers, 3 medullar cancers, 51 papillary cancers and 1 poorly differentiated cancer. The gene expression profiles were annotated with the clinical and histological diagnoses and, for papillary cancers, with <italic>BRAF</italic> gene V600E mutation status. Gene expression data were obtained using the same equipment, reagents, and protocols as for the previously published ANTE database, including six profiles for healthy thyroid tissues [<xref rid="bib30" ref-type="bibr">30</xref>]. DNA repair molecular pathway analysis showed strongly upregulated pathway activation levels for most of the differential pathways in the papillary cancer and moderately upregulated pattern in the follicular cancer, when compared to the follicular adenomas. This was observed in the BRCA1, ATM, p53, excision repair, and mismatch repair pathways. However, the G2/M checkpoint pathway followed the opposite trend. We also analyzed gene expression patterns linked with the radioiodine resistant thyroid tumors (n = 13) and identified 871 differential genes that according to Gene Ontology analysis formed two functional groups: (i) response to topologically incorrect protein and (ii) aldo-keto reductase (NADP) activity. We also found RNA sequencing reads for two hybrid transcripts: one in-frame fusion for well-known <italic>NCOA4-RET</italic> translocation, and another frameshift fusion of <italic>ALK</italic> oncogene with a new partner <italic>ARHGAP12</italic>. The latter could probably support increased expression of truncated <italic>ALK</italic> downstream from 4<sup>th</sup> exon out of 28. The differences in DNA repair activation patterns may help to improve therapy of different thyroid cancer types under investigation and the data communicated may serve for finding additional markers of radioiodine resistance.</p></sec><sec id="sec2"><label>2</label><title>Results</title><sec id="sec2.1"><label>2.1</label><title>Expression of known molecular mRNA markers of thyroid cancer</title><p id="p0040">Overall, 51 papillary thyroid cancer (PC), 23 follicular thyroid cancer (FC), 3 medullary thyroid cancer (MC), 1 poorly differentiated thyroid cancer (PDC), and 17 follicular thyroid adenoma (FA) samples were investigated. Clinical annotations and quality control metrics of tumor specimens investigated are summarized in the Supplementary files 1 and 2.</p><p id="p0045">To initially characterize molecular data presented here we analyzed expression levels of several mRNA molecules previously reported to be differentially regulated in thyroid tumors. For example, <italic>SERPINA1</italic> [<xref rid="bib30" ref-type="bibr">30</xref>], <italic>LAMB3</italic> [<xref rid="bib31" ref-type="bibr">31</xref>], and <italic>TACSTD2</italic> [<xref rid="bib32" ref-type="bibr">32</xref>] genes are known to be overexpressed in PC, which was also the case in our dataset (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>, Supplementary file 3). On the other hand, in line with the overall mediocre concordance between FC expression biomarkers reported in the previous studies, we did not observe any differences between FA and FC samples for two out of four marker genes proposed in a recent meta-analysis paper [<xref rid="bib25" ref-type="bibr">25</xref>]: <italic>CPQ</italic> and <italic>TFF3</italic>. However, the other two other marker genes <italic>ACVRL1</italic> and <italic>PLVAP</italic> demonstrated upregulated trends in FA versus other tumors (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>, Supplementary file 3).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Differential expression of previously reported marker genes in different thyroid tumor types. Genes <italic>SERPINA1, TACSTD2, LAMB3</italic> were reported as the markers upregulated in PC; genes <italic>ACVRL1, PLVAP, TFF3</italic> and <italic>CPQ</italic> were reported as the markers upregulated in FA. Each box shows gene expression distribution in each group, the ends of the box are the upper and lower quartiles, median in shown by horizontal line inside the boxes, whiskers extend from the upper and lower hinges of the boxes towards the highest and lowest values, respectively, at most 1.5 &#x02217; interquartile range of box. A black point corresponds to a tissue sample. Expression counts were processed as reads per million (RPM).</p></caption><alt-text id="alttext0055">Figure&#x000a0;1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="p0050">We also compared expression of sodium iodide symporter gene <italic>SLC5A5</italic> in the biosamples from tumors, which were resistant to radioactive iodine therapy, with all other thyroid tumors profiled in this study. In line with the previous data [<xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>], in our dataset <italic>SLC5A5</italic> was statistically significantly downregulated (p = 3.44&#x02217;10<sup>&#x02212;3</sup>) in radioactive iodine-resistant tumor samples (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>).<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Differential expression of gene <italic>SLC5A5</italic> in radioactive iodine resistant, sensitive and all other thyroid tumors. Expression &#x02013; DESeq2 normalized read counts. Gene expression values for radioactive iodine resistant tumors (<italic>radioresistance</italic>), sensitive (<italic>radiosensitivity</italic>) thyroid tumors and tumors with undefined radioactive iodine therapy status profiled in this study are boxed. Gene expression is plotted in the log10-trasformed scale. Each box shows gene expression distribution in each group, the ends of the box are the upper and lower quartiles, median in shown by horizontal line inside the boxes, whiskers extend from the upper and lower hinges of the boxes towards the highest and lowest values, respectively, at most 1.5 &#x02217; interquartile range of box. A black point corresponds to a tissue sample. Drawn using ggplot package in R.</p></caption><alt-text id="alttext0060">Figure&#x000a0;2</alt-text><graphic xlink:href="gr2"/></fig></p><p id="p0055">Thyroid hormone biosynthesis requires active hydrogen peroxide production which may also be responsible for the high level of oxidative DNA damage. The NADPH oxidase/dual oxidase family members are the only known oxidoreductases whose primary function is production of reactive oxygen species, and their increased expression levels were previously shown in thyroid cancer [<xref rid="bib36" ref-type="bibr">36</xref>]. We compared expressions of <italic>NOX1, NOX3, NOX4, NOX5, DUOX1,</italic> and <italic>DUOX2</italic> genes in our experimental FA, FC, and PC samples and found no significant differences between the above thyroid tumor types (data not shown).</p></sec><sec id="sec2.2"><label>2.2</label><title>BRAF (V600E) mutation status</title><p id="p0060">In PC patients, <italic>BRAF</italic> (V600E) mutation status is an important diagnostic and prognostic biomarker for tumor aggressiveness and relapse [<xref rid="bib37" ref-type="bibr">37</xref>]. We therefore screened all PC specimens for this mutation and identified 15 mutant and 27 wild-type cases (Supplementary file 1). Notably, neither PCA nor Euclidean distance-based hierarchical clustering identified any specific pattern associated with mutated or wild-type status <italic>BRAF</italic> V600E in the tumor samples (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>). We found no differentially expressed genes with q &#x0003c; 0.1 by Wilcoxon test for the groups of <italic>BRAF</italic> (V600E) mutation positive and negative PCs.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p><italic>BRAF</italic> V600E mutation status in PC samples. A &#x02013; plot for principle component analysis in normalized gene expression space for all PC profiles investigated. B &#x02013; hierarchical clustering based on Euclidian distance in gene space in relation to <italic>BRAF</italic> V600E mutation status. Drawn using ggplot package in R, clustering algorithm &#x0201c;ward.d2&#x0201d;. Expression counts were normalized with DESeq2.</p></caption><alt-text id="alttext0065">Figure&#x000a0;3</alt-text><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec2.3"><label>2.3</label><title>Activities of DNA repair pathways in different types of thyroid tumors</title><p id="p0065">We then attempted to evaluate the differences in the activities of DNA repair pathways between the normal thyroid samples, benign tumors, and thyroid cancer subtypes.</p><p id="p0070">Pathway activation level (PAL) is an integral parameter that characterizes activation of a molecular pathway using high-throughput gene expression data [<xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>]. It utilizes aggregation of logarithmic fold-change expression levels (case compared with control samples) for the gene products involved in a certain molecular pathway, using functional flags indicating specific activator or repressor roles of a gene product in the molecular pathway [<xref rid="bib38" ref-type="bibr">38</xref>]. Positive PAL value indicates upregulation of the molecular pathway, negative value &#x02013; its downregulation, whereas zero means unaffected level compared with the controls [<xref rid="bib38" ref-type="bibr">38</xref>].</p><p id="p0075">For our assay, we selected 38 DNA repair pathways, which were obtained by manual curation of Reactome [<xref rid="bib40" ref-type="bibr">40</xref>], NCI Pathway Interaction [<xref rid="bib41" ref-type="bibr">41</xref>], Kyoto Encyclopedia of Genes and Genomes [<xref rid="bib42" ref-type="bibr">42</xref>], Biocarta [<xref rid="bib43" ref-type="bibr">43</xref>], and Qiagen [<xref rid="bib44" ref-type="bibr">44</xref>] databases, and which include at least ten gene products. For these pathways, we then calculated PAL values for the tumor samples while taking six healthy thyroid tissue gene expression profiles from ANTE database [<xref rid="bib45" ref-type="bibr">45</xref>] as the controls. Then we compared PAL values for the selected DNA repair pathways between the normal samples, benign tumors, and the thyroid cancer subtypes. In total, we performed nine comparisons to assess differential PAL activation trends: malignant and benign (PC + FC + FA) were compared with the normal samples (<italic>i</italic>); follicular adenoma (FA) was compared with the normal samples (<italic>ii</italic>); FC and PC were compared with normal samples (<italic>iii</italic>); FC and PC were compared with FA (<italic>iv</italic>); FC was compared with PC (<italic>v</italic>), FA was compared with FC (<italic>vi</italic>); PC was compared with FA (<italic>vii</italic>), PC was compared with the normal samples (<italic>viii</italic>); and FC was compared with the normal samples (<italic>ix</italic>).</p><p id="p0080">We found statistically significantly differentially regulated DNA repair pathways in only three out of these nine comparisons (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, Supplementary File 4). In particular, six pathways were differential in the comparison (<italic>iv</italic>) FC + PC vs FA; four pathways were differential in the comparison (<italic>v</italic>) FC vs PC; twelve pathways were differential in the comparison (<italic>vii</italic>) PC vs FA (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Alterations of pathway activation levels for 38 DNA repair pathways in differential comparisons of follicular adenoma (FA), follicular cancer (FC), and papillary cancer (PC) tissues.</p></caption><alt-text id="alttext0155">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Pathway ID</th><th>Pathway name</th><th>PC vs FC<xref rid="tbl1fn1" ref-type="table-fn">1</xref><sup>,</sup><xref rid="tbl1fn2" ref-type="table-fn">2</xref></th><th>FC + PC vs FA<xref rid="tbl1fn2" ref-type="table-fn">2</xref><sup>,</sup><xref rid="tbl1fn3" ref-type="table-fn">3</xref></th><th>PC vs FA<xref rid="tbl1fn2" ref-type="table-fn">2</xref><sup>,</sup><xref rid="tbl1fn4" ref-type="table-fn">4</xref></th></tr></thead><tbody><tr><td>p1</td><td>ATM Pathway</td><td>&#x02191;, 2.8e-02</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 4.1e-02</td><td>&#x02191;, 3.6e-03</td></tr><tr><td>p2</td><td>ATM Pathway Cell Survival</td><td>&#x02191;, 1.5e-02</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 6.8e-02</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 8.7e-03</td></tr><tr><td>p3</td><td>ATM Pathway G2-Mitosis progression</td><td>&#x02191;, 1.4e-02</td><td>&#x02193;, 9.8e-01</td><td>&#x02191;, 3.3e-01</td></tr><tr><td>p4</td><td>Biocarta atm signaling pathway</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 8.3e-01</td><td>&#x02191;, 4.0e-01</td><td>&#x02191;, 4.7e-01</td></tr><tr><td>p5</td><td>Biocarta cell cycle G2M checkpoint pathway</td><td>&#x02193;, 2.8e-02</td><td>&#x02193;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 4.1e-02</td><td>&#x02193;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 8.1e-04</td></tr><tr><td>p6</td><td>BRCA1 Pathway</td><td>&#x02191;, 1.0e+00</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 4.2e-02</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 2.8e-02</td></tr><tr><td>p7</td><td>BRCA1 Pathway Chromatin Remodeling</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 1.5e-01</td><td>&#x02191;, 1.3e-01</td><td>&#x02191;, 9.8e-02</td></tr><tr><td>p8</td><td>BRCA1 Pathway Homologous Recombination Repair</td><td>&#x02193;, 1.1e-01</td><td>&#x02191;, 8.5e-02</td><td>&#x02191;, 1.9e-01</td></tr><tr><td>p9</td><td>BRCA1 Pathway Mismatch Repair</td><td>&#x02193;, 9.8e-02</td><td>&#x02191;, 1.7e-01</td><td>&#x02191;, 4.1e-01</td></tr><tr><td>p10</td><td>DNA Repair Mechanisms Pathway</td><td>&#x02191;, 5.6e-01</td><td>&#x02191;, 8.5e-02</td><td>&#x02191;, 6.4e-02</td></tr><tr><td>p11</td><td>KEGG Base excision repair pathway</td><td>&#x02191;, 2.8e-02</td><td>&#x02191;, 8.5e-02</td><td>&#x02191;, 2.0e-02</td></tr><tr><td>p12</td><td>KEGG Fanconi anemia pathway</td><td>&#x02193;, 1.7e-02</td><td>&#x02191;, 8.7e-01</td><td>&#x02193;, 4.8e-01</td></tr><tr><td>p13</td><td>KEGG Homologous recombination pathway</td><td>&#x02191;, 2.5e-01</td><td>&#x02191;, 8.5e-02</td><td>&#x02191;, 3.4e-02</td></tr><tr><td>p14</td><td>KEGG Mismatch repair pathway</td><td>&#x02193;, 1.0e+00</td><td>&#x02191;, 1.4e-01</td><td>&#x02191;, 1.9e-01</td></tr><tr><td>p15</td><td>KEGG Non homologous end joining pathway</td><td>&#x02191;, 1.0e+00</td><td>&#x02191;, 1.4e-01</td><td>&#x02191;, 1.9e-01</td></tr><tr><td>p16</td><td>KEGG Nucleotide excision repair pathway</td><td>&#x02193;, 5.6e-01</td><td>&#x02191;, 1.0e-01</td><td>&#x02191;, 1.6e-01</td></tr><tr><td>p17</td><td>Mismatch Repair in Eukaryotes Pathway</td><td>&#x02193;, 7.7e-01</td><td>&#x02191;, 8.5e-02</td><td>&#x02191;, 9.8e-02</td></tr><tr><td>p18</td><td>NCI ATM pathway</td><td>&#x02191;, 2.5e-01</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 4.1e-02</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 1.5e-02</td></tr><tr><td>p19</td><td>NCI ATM Pathway (G1 S transition checkpoint)</td><td>&#x02191;, 6.5e-01</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 4.1e-02</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 1.6e-02</td></tr><tr><td>p20</td><td>NCI ATR signaling pathway</td><td>&#x02193;, 2.1e-01</td><td>&#x02191;, 1.4e-01</td><td>&#x02191;, 2.7e-01</td></tr><tr><td>p21</td><td>NCI ATR signaling Pathway (Pathway negative regulation of transcription during mitosis via CHEK1)</td><td>&#x02193;, 2.1e-01</td><td>&#x02191;, 1.7e-01</td><td>&#x02191;, 3.2e-01</td></tr><tr><td>p22</td><td>NCI ATR signaling Pathway (regulation of double strand break repair via homologous recombination)</td><td>&#x02193;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 1.8e-01</td><td>&#x02191;, 1.2e-01</td><td>&#x02191;, 2.2e-01</td></tr><tr><td>p23</td><td>NCI ATR signaling Pathway (response to G2 M transition DNA damage checkpoint signal)</td><td>&#x02193;, 2.1e-01</td><td>&#x02191;, 1.8e-01</td><td>&#x02191;, 3.4e-01</td></tr><tr><td>p24</td><td>NCI DNA PK pathway in nonhomologous end joining Pathway (double strand break repair via nonhomologous end joining)</td><td>&#x02191;, 5.6e-01</td><td>&#x02191;, 1.4e-01</td><td>&#x02191;, 1.4e-01</td></tr><tr><td>p25</td><td>NCI DNA PK pathway in nonhomologous end joining Pathway (V D J recombination)</td><td>&#x02191;, 1.0e+00</td><td>&#x02191;, 1.7e-01</td><td>&#x02191;, 2.2e-01</td></tr><tr><td>p26</td><td>NCI Fanconi anemia pathway</td><td>&#x02193;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 1.5e-01</td><td>&#x02191;, 1.1e-01</td><td>&#x02191;, 2.2e-01</td></tr><tr><td>p27</td><td>NCI Fanconi anemia Pathway (regulation of double strand break repair via homologous recombination)</td><td>&#x02193;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 1.5e-01</td><td>&#x02191;, 1.0e-01</td><td>&#x02191;, 2.0e-01</td></tr><tr><td>p28</td><td>NCI Fanconi anemia Pathway (Sister Chromatid Exchange Process)</td><td>&#x02193;, 2.1e-01</td><td>&#x02191;, 1.7e-01</td><td>&#x02191;, 3.1e-01</td></tr><tr><td>p29</td><td>NHEJ mechanisms of DSBs repair effect</td><td>&#x02193;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 2.8e-01</td><td>&#x02191;, 1.4e-01</td><td>&#x02191;, 2.6e-01</td></tr><tr><td>p30</td><td>Nucleotide excision repair effect</td><td>&#x02191;, 1.1e-01</td><td>&#x02191;, 5.0e-02</td><td>&#x02191;, 1.1e-02</td></tr><tr><td>p31</td><td>p53 Signaling Pathway</td><td>&#x02191;, 2.0e-03</td><td>&#x02191;, 4.1e-02</td><td>&#x02191;, 8.1e-04</td></tr><tr><td>p32</td><td>p53 Signaling Pathway DNA Repair</td><td>&#x02191;, 5.3e-01</td><td>&#x02191;, 1.4e-01</td><td>&#x02191;, 9.8e-02</td></tr><tr><td>p33</td><td>p53 Signaling Pathway Gene Expression DNA Replication and Repair via TP53</td><td>&#x02191;, 7.2e-02</td><td>&#x02191;, 9.1e-02</td><td>&#x02191;, 3.4e-02</td></tr><tr><td>p34</td><td>reactome Fanconi Anemia pathway</td><td>&#x02191;, 7.7e-01</td><td>&#x02191;, 1.1e-01</td><td>&#x02191;, 9.8e-02</td></tr><tr><td>p35</td><td>Reactome Formation of transcription coupled NER TC NER repair complex pathway</td><td>&#x02191;, 1.0e+00</td><td>&#x02191;, 1.7e-01</td><td>&#x02191;, 2.2e-01</td></tr><tr><td>p36</td><td>Reactome Mismatch repair MMR directed by MSH2, MSH3, MutSbeta pathway</td><td>&#x02191;, 1.3e-01</td><td>&#x02191;, 8.5e-02</td><td>&#x02191;, 3.4e-02</td></tr><tr><td>p37</td><td>Reactome Mismatch repair MMR directed by MSH2, MSH6, MutSalpha pathway</td><td>&#x02191;, 9.8e-02</td><td>&#x02191;, 6.1e-02</td><td>&#x02191;, 1.6e-02</td></tr><tr><td>p38</td><td>Reactome Repair synthesis for gap filling by DNA polymerase in TC NER pathway</td><td>&#x02191;, 5.0e-01</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 1.0e-01</td><td>&#x02191;<xref rid="tbl1fn5" ref-type="table-fn">5</xref>, 7.4e-02</td></tr></tbody></table><table-wrap-foot><fn id="tbl1fn1"><label>1</label><p id="ntpara0010">Comparison of papillary cancer versus follicular cancer tissues.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn2"><label>2</label><p id="ntpara0015">q-value (FDR-adjusted p-value) for Wilcoxon test is given for every molecular pathway PAL in every comparison. Sign &#x0201c;&#x02191;&#x0201d; means that the first comparative group has higher mean PAL than the second, sign &#x0201c;&#x02193;&#x0201d; denotes the opposite situation.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn3"><label>3</label><p id="ntpara0020">Comparison of follicular and papillary cancer tissues versus follicular adenoma.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn4"><label>4</label><p id="ntpara0025">Comparison of papillary cancer versus follicular adenoma tissues.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn5"><label>5</label><p id="ntpara0030">The coefficient of quartile variation (CQV) is higher for compared groups together than for each separate group.</p></fn></table-wrap-foot></table-wrap></p><p id="p0085">The boxplot presentations of PAL values for all differential pathway comparisons are shown in <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>. We also assessed variation of each group under comparison separately and together, both on pathway (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, Supplementary file 4) and gene levels (Supplementary file 5). We calculated the following statistical characteristics: mean, standard deviation, interquartile range (IQR), Range (the difference between maximum and minimum), ratio of IQR and Range, the coefficient of quartile variation (CQV), confidence interval (CI) for CQV (Supplementary file 4). At the level of pathway activation, CQV was calculated for (PAL-minimal (PAL)) because PAL can take negative values [<xref rid="bib46" ref-type="bibr">46</xref>]. We marked the pathways, for which CQV of two compared groups together was higher than CQV of each separate group (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, Supplementary file 4), there were six such differential pathways (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>): <italic>ATM Pathway, ATM Pathway Cell Survival, BRCA1 Pathway, NCI ATM pathway, NCI ATM Pathway (G1 S transition checkpoint), Biocarta cell cycle G2M checkpoint pathway</italic>.<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Boxplot representation of PAL values for the differential pathways corresponding to comparisons from <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. Pathway name abbreviations: p1 - ATM Pathway, p2 - ATM Pathway Cell Survival, p3 - ATM Pathway G2-Mitosis progression, p5 - Biocarta cell cycle G2M checkpoint pathway, p6 - BRCA1 Pathway, p11 - KEGG Base excision repair pathway, p12 - KEGG Mismatch repair pathway, p13 - KEGG Nucleotide excision repair pathway, p18 - NCI ATM pathway, p19 - NCI ATM Pathway (G1 S transition checkpoint), p30 - Nucleotide excision repair effect, p31 - p53 Signaling Pathway, p33 - p53 Signaling Pathway Gene Expression DNA Replication and Repair via TP53, p36 - Reactome Mismatch repair MMR directed by MSH2, MSH3, MutS beta pathway, p37 - Reactome Mismatch repair MMR directed by MSH2, MSH6, MutS alpha pathway.</p></caption><alt-text id="alttext0070">Figure&#x000a0;4</alt-text><graphic xlink:href="gr4"/></fig></p><p id="p0090">We then applied the same comparison parameters for individual DNA repair pathway member genes to identify genes which contribute to differential regulation of the pathways (Supplementary file 5). For example, Biocarta cell cycle G2M checkpoint pathway had seven differentially expressed genes for PC vs FA comparison (<italic>ATR, CCNB1, CDKN2D, MDM2, PI4KA, RASGRF1, SFN</italic>), Supplementary file 5. Most of differential genes were up-regulated in PC (Supplementary file 5) which resulted in up-regulation of most of the pathways. However, <italic>Biocarta cell cycle G2M checkpoint pathway</italic> was down-regulated in PC because most of the differential genes have negative activator/repressor role coefficients (ARR) for this pathway [<xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib47" ref-type="bibr">47</xref>].</p><p id="p0095">In total, 15 individual DNA repair pathways were differential in at least one comparison. Among them, five pathways were differential simultaneously in two comparisons, and three &#x02013; in three comparisons (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>).</p><p id="p0100">While PAL values were positive for certain pathways in PC and FC, the PAL differences between the tumors and normal thyroid samples were not significant. To test that we calculated PAL level for each normal sample (Supplementary file 6). PAL level for a normal sample can be interpreted as an activation level of a pathway in a normal sample when compared to the average of all normal samples. This is needed to test the significance of the differences when comparing the group of normal samples with other groups. Lack of significance between normal samples and tumors is linked with a high heterogeneity of PAL values in normal samples (Supplementary file 4).</p><p id="p0105">Thus, no pathway activation changes distinctive for all tumor types versus normal samples have been found. There were also no differentially regulated patterns between all benign and malignant thyroid neoplasms. We conclude, therefore, that we could not identify marker DNA repair pathway alterations for thyroid tumorigenesis in general, but several DNA repair pathways were characteristic for follicular and papillary neoplasms.</p><p id="p0110">We then assessed clustering of thyroid tumors according to the PAL values of fifteen DNA repair pathways found to be significantly differential in the previous comparisons (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>). We observed a trend with either PC-, or FC and FA-enriched clusters (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>). Unlike the other cancer types, the PC samples had mostly positive PAL values for the DNA repair pathways, which suggested their overall stronger activation. However, there were also two pathways related to passing through G2 phase of the cell cycle, that were downregulated in most of the thyroid cancer specimens including PC: <italic>ATM Pathway G2-Mitosis progression</italic> and <italic>Biocarta cell cycle g2 m checkpoint pathway</italic>.<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Heatmap of pathway activation levels for 15 differential DNA repair pathways in all thyroid tumor samples investigated.</p></caption><alt-text id="alttext0075">Figure&#x000a0;5</alt-text><graphic xlink:href="gr5"/></fig></p><p id="p0115">To further characterize tumor type-specific pathway activation profiles, we used average PAL values to build radar-charts for the 15 differential DNA repair pathways for the FA, FC, and PC tumor types (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref> A,D,G). We did not consider medullar thyroid cancer and poorly differentiated thyroid cancer because these tumor types did not have enough samples to enable statistically robust investigation. For most of the pathways, this analysis revealed downregulated activation pattern in FA, strongly enhanced pattern in PC, and intermediate pattern in FC (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>, A,D,G). However, the observed activation patterns did not relate to the two pathways associated with passing through the G2 phase of the cell cycle. The <italic>ATM Pathway G2-Mitosis progression</italic> pathway was strongly downregulated in all the tumor types investigated. The <italic>Biocarta cell cycle g2 m checkpoint pathway</italic> showed another trend: it was upregulated in FA and to a lesser extent in FC, and downregulated in PC (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>, A,D,G).<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Radar-charts of 15 differential DNA repair pathway activation profile for (A) follicular adenoma, ANTE normal samples used for PAL calculation, (B) follicular adenoma, GTEx normal samples used for PAL calculation, (C) follicular adenoma, TCGA normal samples used for PAL calculation, (D) follicular cancer, ANTE normal samples used for PAL calculation, (E) follicular cancer, CTEx normal samples used for PAL calculation, (F) follicular cancer, TCGA normal samples used for PAL calculation, (G) papillary cancer, ANTE normal samples used for PAL calculation, (H) papillary cancer, GTEx normal samples used for PAL calculation, (I) papillary cancer, TCGA normal samples used for PAL calculation. Positive pathway activation values (PALs) are shown in the outer white area, negative values &#x02013;in the inner red circle area.</p></caption><alt-text id="alttext0080">Figure&#x000a0;6</alt-text><graphic xlink:href="gr6"/></fig></p><p id="p0120">We repeated the above comparative analysis with greater amount of control samples by using normal thyroid RNA sequencing profiles from public databases GTEx (446 samples) and TCGA (58 samples) which showed, however, strong platform-specific bias (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>). Unlike for the ANTE dataset, different equipment, reagents and protocols for RNA isolation, ribosomal RNA depletion, library preparation and sequencing were used for the GTEx and TCGA data. This led to significant changes of the absolute pathway activation levels when calculated using GTEx and TCGA norms (Supplementary File 4). However, the intratumoral comparisons resulted in the same conclusions as before, and we obtained the same 15 differential pathways using both types of new normal datasets (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>, Supplementary File 4). Although pathway activation level (PAL) values depended on the normal dataset used, the trends of PAL expression in thyroid tumor types was consistent regardless of the normal set used: minimal overall activation of DNA repair pathways in FA samples (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref> A, B, C), medium in FC samples (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref> D,E,F), and maximal in PC samples (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6 G,H,</xref>I).<fig id="fig7"><label>Figure&#x000a0;7</label><caption><p>Principal component analysis of gene expression profiles for experimental thyroid tumor samples, and normal thyroid tissue samples from ANTE, GTEx and TCGA databases.</p></caption><alt-text id="alttext0085">Figure&#x000a0;7</alt-text><graphic xlink:href="gr7"/></fig></p><p id="p0125">We then reconstructed the joint molecular networks by combining the differential DNA repair pathways for each of the above three comparisons (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>): PC vs FC, PC + FC vs FA, and PC vs FA (Figures&#x000a0;<xref rid="fig3" ref-type="fig">3</xref>, <xref rid="fig4" ref-type="fig">4</xref>, and <xref rid="fig5" ref-type="fig">5</xref>, Supplementary file 5). For example, the joined network for the comparison &#x0201c;FC vs PC&#x0201d; included <italic>p53 signaling pathway, KEGG Base excision repair pathway, biocarta cell cycle g2 m checkpoint pathway</italic>, <italic>KEGG Fanconi anemia pathway</italic> and <italic>ATM pathway</italic> with its branches <italic>responsible for cell survival</italic> (<italic>i</italic>) and <italic>passing through G2 stage during cell cycle progression</italic> (<italic>ii</italic>) (<xref rid="fig8" ref-type="fig">Figure&#x000a0;8</xref>).<fig id="fig8"><label>Figure&#x000a0;8</label><caption><p>Reconstructed differential DNA repair molecular network for the comparison of Papillary cancer (PC) vs Follicular cancer (FC). Node Fold Change for each node was calculated as the sum of fold changes for the genes which were included in the node. Fold change for each gene was calculated by taking logarithm base 2 of ratio of geometric means of gene expression in compared groups. Green nodes represent genes that are up-regulated in PC (down-regulated in FC); red nodes - genes that are down-regulated in PC (up-regulated in FC). Arrow color indicates type of interaction. Shape of a node reflects source molecular pathway(s). Asterisks (&#x02217;) indicate nodes which include differential genes (PC vs FC) with q-value &#x0003c;0.05; double asterisks (&#x02217;&#x02217;) - nodes which include differential genes with q &#x0003c; 0.01. ATM pathway represented here also includes its differentially regulated branches that can be considered as separate pathways: <italic>ATM Pathway Cell Survival</italic> and <italic>ATM Pathway G2-Mitosis progression</italic>.</p></caption><alt-text id="alttext0090">Figure&#x000a0;8</alt-text><graphic xlink:href="gr8"/></fig></p><p id="p0130">Overall, in PC compared with FC, we detected upregulated <italic>ATM, p53 and base excision repair pathways</italic> and downregulated <italic>KEGG Fanconi anemia and cell cycle g2-m checkpoint pathways</italic> (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>). <italic>P53 signaling pathway</italic> is involved in many mechanisms of DNA repair [<xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>]. ATM-related pathways participate in double strand DNA breaks repair [<xref rid="bib46" ref-type="bibr">46</xref>]. Fanconi anemia pathway coordinate a complex mechanism that enlists elements of three classic DNA repair types: homologous recombination, nucleotide excision repair, and mutagenic translesion synthesis in response to genotoxic insults [<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib47" ref-type="bibr">47</xref>]. Thus, we can highlight that PC compared with FC has more active double strand DNA breaks repair and base excision repair pathways, and also more intensively involves homologous recombination, nucleotide excision repair, and mutagenic translesion synthesis mechanisms.</p><p id="p0135">Furthermore, when comparing PC + FC versus FA, in addition to the upregulated <italic>ATM and p53 pathways</italic> we also detected upregulated <italic>BRCA1 pathway</italic> and <italic>NCI ATM pathway</italic> with its branch <italic>G1 S transition checkpoint</italic>. In turn, the <italic>Cell cycle G2M checkpoint pathway</italic> was downregulated in PC + FC compared with FA (<xref rid="fig9" ref-type="fig">Figure&#x000a0;9</xref>, <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>). <italic>G1 S transition checkpoint</italic> branch of <italic>NCI ATM pathway</italic> was upregulated, unlike the G2M checkpoint pathway. The <italic>BRCA1 pathway</italic> is responsible for the regulation of DNA damage-induced cell cycle checkpoints and controls multiple DNA repair processes, including homologous recombination, non-homologous end-joining, and single-strand annealing [<xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>]. Thus, we conclude that PC + FC have higher activation levels of double strand DNA breaks repair, if compared with FA.<fig id="fig9"><label>Figure&#x000a0;9</label><caption><p>Reconstructed differential DNA repair molecular network for the comparison of Follicular and Papillary cancers (FC + PC) vs Follicular adenoma (FA). Node Fold Change for each node was calculated as the sum of fold changes of the genes which were included in the node. Fold change for each gene was calculated by taking logarithm base 2 of ratio of geometric means of gene expression in compared groups. Green nodes represent genes that are up-regulated in FC + PC (down-regulated in FA); red nodes &#x02013; genes that are down-regulated in FC + PC (up-regulated in FA). Arrow color indicates type of interaction. Shape of a node reflects source molecular pathway(s). Asterisks (&#x02217;) indicate nodes which include differential genes (FC + PC vs FA) with q-value &#x0003c;0.05; double asterisks (&#x02217;&#x02217;) - nodes which include differential genes with q &#x0003c; 0.01. NCI ATM pathway represented here also includes its differentially regulated branch that can be considered as separate pathway - <italic>G1 S transition checkpoint</italic>.</p></caption><alt-text id="alttext0095">Figure&#x000a0;9</alt-text><graphic xlink:href="gr9"/></fig></p><p id="p0140">Finally, in the comparison of PC vs FA we observed the greatest number of differential pathways. The previously mentioned pathways (<italic>ATM pathway</italic> with its branch <italic>Cell Survival, p53 pathway, BRCA1 pathway, Biocarta cell cycle G2M checkpoint pathway, KEGG Base excision repair pathway</italic>) followed the same regulation trends, but there were also several new pathways. These were <italic>KEGG Homologous recombination pathway</italic>, <italic>Nucleotide excision repair effect pathway, Reactome Mismatch repair MMR directed by MSH2, MSH6, MutSalpha pathway</italic>, <italic>Reactome Mismatch repair MMR directed by MSH2, MSH3, MutS beta pathway</italic>, and specific branch of p53 pathway <italic>Gene Expression DNA Replication and Repair via TP53</italic> (<xref rid="fig10" ref-type="fig">Figure&#x000a0;10</xref>, <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>). All the pathways were upregulated in PC compared with FA except for the cell cycle G2M checkpoint pathway, which was downregulated. We, therefore, conclude that PC, if compared with FA, had more active double strand DNA breaks repair, nucleotide excision and mismatch repair mechanisms, but less active G2M checkpoint transition pathway.<fig id="fig10"><label>Figure&#x000a0;10</label><caption><p>Reconstructed differential DNA repair molecular network for the comparison of Papillary cancer (PC) vs Follicular adenoma (FA). Node Fold Change for each node was calculated as the sum of fold changes of the genes which were included in the node. Fold change for each gene was calculated by taking logarithm base 2 of ratio of geometric means of gene expression in compared groups. Green nodes represent genes that are up-regulated in PC (down-regulated in FA); red nodes &#x02013; genes that are down-regulated in PC (up-regulated in FA). Arrow color indicates type of interaction. Shape of a node reflects source molecular pathway(s). Asterisks (&#x02217;) indicate nodes which include differential genes (PC vs FA) with q-value &#x0003c;0.05; double asterisks (&#x02217;&#x02217;) - nodes which include differential genes with q &#x0003c; 0.01. ATM pathway, NCI ATM pathway, and p53 signaling pathway represented here also include their differentially regulated branches that can be considered as separate pathways: <italic>Cell Survival, G1 S transition checkpoint</italic>, and <italic>Gene Expression DNA Replication and Repair via TP53</italic>, accordingly.</p></caption><alt-text id="alttext0100">Figure&#x000a0;10</alt-text><graphic xlink:href="gr10"/></fig></p><p id="p0145">We then analyzed gene compositions of the reconstructed comparison-specific DNA repair networks and found statistically significantly differential genes (according to Wilcoxon test) that may represent the key regulated pathway nodes. We adjusted Wilcoxon <italic>p</italic>-value by Benjamini-Hochberg false discovery rate test and obtained the differential gene set with <italic>q</italic>-value less than 0.05 for each reconstructed pathway: totally 68, 73, and 91 genes for the three comparisons, respectively (Supplementary file 5). The gene compositions in these three lists were highly redundant and totally represented 96 individual genes. Top-10 of these differential genes sorted by the fold change value are shown on <xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>.<table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Top 10 differential DNA repair genes for thyroid tumor comparisons.</p></caption><alt-text id="alttext0160">Table&#x000a0;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Gene ID</th><th>PC vs FC <xref rid="tbl2fn1" ref-type="table-fn">1</xref><sup>,</sup><xref rid="tbl2fn2" ref-type="table-fn">2</xref></th><th>FC + PC vs FA<xref rid="tbl2fn2" ref-type="table-fn">2</xref><sup>,</sup><xref rid="tbl2fn3" ref-type="table-fn">3</xref></th><th>PC vs FA<xref rid="tbl2fn2" ref-type="table-fn">2</xref><sup>,</sup><xref rid="tbl2fn4" ref-type="table-fn">4</xref></th><th>Gene product function according to GeneCards database [<xref rid="bib62" ref-type="bibr">62</xref>]</th></tr></thead><tbody><tr><td><italic>SFN</italic></td><td>1.42</td><td>1.62</td><td>2.06</td><td>Cell cycle checkpoint protein, regulates mitotic translation by binding with translation initiation factors</td></tr><tr><td><italic>RAC2</italic></td><td>1.40</td><td>0.37</td><td>0.80</td><td>Metabolizes small guanosine triphosphate (GTP) and thus regulates secretion, phagocytosis, cell polarization, motility, etc</td></tr><tr><td><italic>RASGRF1</italic></td><td>1.35</td><td>1.27</td><td>1.68</td><td>Stimulates dissociation of GDP from RAS proteins</td></tr><tr><td><italic>IGF2</italic></td><td>1.18</td><td>0.56</td><td>0.93</td><td>Insulin growth factor involved in growth and development</td></tr><tr><td><italic>IRF9</italic></td><td>1.00</td><td>-</td><td>-</td><td>Transcription factor mediating interferon signaling by IFN-alpha and IFN-beta</td></tr><tr><td><italic>JUN</italic></td><td>0.90</td><td>-</td><td>-</td><td>Transcription factor that recognizes and binds to the enhancer heptamer motif 5&#x02032;-TGA[CG]TCA-3&#x02032;</td></tr><tr><td><italic>POLD4</italic></td><td>0.89</td><td>-</td><td>-</td><td>Enhances the activity of DNA polymerase delta and takes part in replication fork repair and stabilization</td></tr><tr><td><italic>ADGRB1</italic></td><td>-0.87</td><td>-</td><td>-</td><td>Adhesion G Protein-Coupled Receptor B1 enhances the engulfment of apoptotic cells. Activates the Rho pathway in a G-protein-dependent manner</td></tr><tr><td><italic>MAP3K11</italic></td><td>0.86</td><td>0.42</td><td>0.69</td><td>Preferentially activates MAPK8/JNK kinase, and functions as a positive regulator of JNK signaling pathway</td></tr><tr><td><italic>MAP3K14</italic></td><td>0.80</td><td>-</td><td>-</td><td>Binds to TRAF2 and stimulates NF-kappaB activity</td></tr><tr><td><italic>ATR</italic></td><td>-</td><td>0.68</td><td>0.86</td><td><italic>S</italic>erine/threonine kinase and DNA damage sensor, activating cell cycle checkpoint signaling upon DNA stress, phosphorylates and activates several proteins involved in the inhibition of DNA replication and mitosis; promotes DNA repair, recombination, and apoptosis.</td></tr><tr><td><italic>CCNB1</italic></td><td>-</td><td>0.53</td><td>0.71</td><td>Regulates mitosis by complexing with p34 to form the maturation-promoting factor necessary for proper control of the G2/M transition phase of the cell cycle.</td></tr><tr><td><italic>CDKN2D</italic></td><td>-</td><td>0.40</td><td>0.64</td><td>Cyclin-dependent kinase inhibitor which forms a stable complex with CDK4 or CDK6, and prevent their activation, thereby regulating cell cycle G1 phase progression.</td></tr><tr><td><italic>MDM2</italic></td><td>-</td><td>0.39</td><td>0.64</td><td>Nuclear-localized E3 ubiquitin ligase which can promote carcinogenesis by targeting for proteasomal degradation tumor suppressor proteins including P53.</td></tr><tr><td><italic>PI4KA</italic></td><td>-</td><td>0.37</td><td>-</td><td>Phosphatidylinositol 4-kinase which catalyzes the first step in the biosynthesis of phosphatidylinositol 4-bisphosphate.</td></tr><tr><td><italic>H2AFX</italic></td><td>-</td><td>-</td><td>0.69</td><td>Variant histone that is phosphorylated as a reaction on DNA double-strand breaks, and replaces conventional H2A histone in nucleosomes</td></tr></tbody></table><table-wrap-foot><fn id="tbl2fn1"><label>1</label><p id="ntpara0035">Comparison of PC versus FC tissues.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn2"><label>2</label><p id="ntpara0040">Gene fold change (log base 2). Sign &#x0201c;-&#x0201d; means that the gene is not included in top-10 of the most up- or downregulated differential genes.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn3"><label>3</label><p id="ntpara0045">Comparison of FC + PC versus FA tissues.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn4"><label>4</label><p id="ntpara0050">Comparison of PC versus FA tissues.</p></fn></table-wrap-foot></table-wrap></p><p id="p0150">In some cases, the transcriptional activity of genes can be unrelated to the corresponding protein levels due to specific translation regulation mechanisms. To investigate whether transcriptional changes reflect DNA repair effector protein concentrations in cancer tissues we used published datasets to assess correlation of expression at the transcriptomic and proteomic levels for four DNA repair effector genes: <italic>ATM, BRCA1, H2AFX</italic>, and <italic>TP53</italic> in different cancers. We found that transcription and protein concentration were statistically significantly positively correlated in most of the cases, which can support adequacy of the transcriptome-based approach to DNA repair pathway analyzes (<xref rid="fig11" ref-type="fig">Figure&#x000a0;11</xref>).<fig id="fig11"><label>Figure&#x000a0;11</label><caption><p>Correlation of expression at transcriptome and proteome levels for <italic>ATM, BRCA1, H2AFX,</italic> and <italic>TP53</italic> genes in six human cancer types.</p></caption><alt-text id="alttext0105">Figure&#x000a0;11</alt-text><graphic xlink:href="gr11"/></fig></p></sec><sec id="sec2.4"><label>2.4</label><title>DNA repair pathway activities in thyroid tumors and in adjacent pathologically normal tissues</title><p id="p0155">We explored previously published thyroid tumor gene expression dataset PRJEB11591 [<xref rid="bib53" ref-type="bibr">53</xref>,<xref rid="bib54" ref-type="bibr">54</xref>] to validate the activation trend revealed for the activities of DNA repair pathways in three types of thyroid tumors. The literature dataset contained RNA sequencing data for 25 FAs, 30 minimally invasive FCs, 48 follicular variants of PC (FVs), 77 classical papillary thyroid carcinomas (PCs) and 81 adjacent pathologically normal thyroid tissues. The adjacent normal samples corresponded to 18 FAs, 19 FCs, 11 FVs and 33 PCs. As before, we performed differential pathway analyses (for 38 DNA repair pathways) and obtained the statistically significant q-value in at least one comparison for 36 out of 38 DNA repair pathways investigated (Supplementary file 7). We used 81 adjacent normal samples as the controls to calculate PAL of DNA repair pathways.</p><p id="p0160">Using these data we confirmed the previously revealed tendency that the majority of differential DNA repair pathways have minimal activation signature in FA, medium in FC and maximal in PC (<xref rid="fig12" ref-type="fig">Figure&#x000a0;12</xref>). FV (follicular variant of PC) had intermediate pathway activation values between FC and PC (<xref rid="fig12" ref-type="fig">Figure&#x000a0;12</xref>). DNA repair pathway activation levels in adjacent pathologically normal tissues were very similar to the levels observed in the corresponding tumors (R Pearson = 0.8492, p-value &#x0003c; 2.2e-16, <xref rid="fig12" ref-type="fig">Figure&#x000a0;12</xref>). This finding may reflect tumor influence on gene expression in adjacent pathologically normal tissue.<fig id="fig12"><label>Figure&#x000a0;12</label><caption><p>Average PAL values for 36 differential DNA repair pathways. (A) calculated using PRJEB11591 dataset for follicular adenoma (FA), follicular cancer (FC), follicular variant of papillary cancer (FV), classical variant of papillary cancer (PC) and their matched adjacent pathologically normal tissues: FA.N, FC.N, FV.N, PC.N, respectively. Pathway name abbreviations: p1 - ATM Pathway, p2 - ATM Pathway Cell Survival, p3 - ATM Pathway G2-Mitosis progression, p4 - Biocarta atm signaling pathway, p5 - Biocarta cell cycle G2M checkpoint pathway, p6 - BRCA1 Pathway, p7 - BRCA1 Pathway Chromatin Remodeling, p8 - BRCA1 Pathway Homologous Recombination Repair, p9 - BRCA1 Pathway Mismatch Repair, p10 - DNA Repair Mechanisms Pathway, p11 - KEGG Base excision repair pathway, p12 - KEGG Fanconi anemia pathway, p13 - KEGG Homologous recombination pathway, p14 - KEGG Mismatch repair pathway, p15 - KEGG Non homologous end joining pathway, p16 - KEGG Nucleotide excision repair pathway, p17 - Mismatch Repair in Eukaryotes Pathway, p18 - NCI ATM pathway, p19 - NCI ATM Pathway (G1 S transition checkpoint), p20 - NCI ATR signaling pathway, p21 - NCI ATR signaling Pathway (Pathway negative regulation of transcription during mitosis via CHEK1), p22 - NCI ATR signaling Pathway (regulation of double strand break repair via homologous recombination), p23 - NCI ATR signaling Pathway (response to G2 M transition DNA damage checkpoint signal), p24 - NCI DNA PK pathway in nonhomologous end joining Pathway (double strand break repair via nonhomologous end joining), p25 - NCI DNA PK pathway in nonhomologous end joining Pathway (V D J recombination), p26 - NCI Fanconi anemia pathway, p27 - NCI Fanconi anemia Pathway (regulation of double strand break repair via homologous recombination), p28 - NCI Fanconi anemia Pathway (Sister Chromatid Exchange Process), p29 - NHEJ mechanisms of DSBs repair effect, p30 - Nucleotide excision repair effect, p31 - p53 Signaling Pathway, p33 - p53 Signaling Pathway Gene Expression DNA Replication and Repair via TP53, p34 - reactome Fanconi Anemia pathway, p36 - Reactome Mismatch repair MMR directed by MSH2, MSH3, MutS beta pathway, p37 - Reactome Mismatch repair MMR directed by MSH2, MSH6, MutS alpha pathway, p38 - Reactome Repair synthesis for gap filling by DNA polymerase in TC NER pathway. (B) Average PAL for tumor tissues and the corresponding adjacent pathologically normal tissues. Each dot represents a "pathway &#x02013; thyroid tumor type" case, totally 144 cases represented (36 pathways in four tumor types).</p></caption><alt-text id="alttext0110">Figure&#x000a0;12</alt-text><graphic xlink:href="gr12"/></fig></p></sec><sec id="sec2.5"><label>2.5</label><title>APOBEC activity in thyroid tumors</title><p id="p0165">Mutational signature of thyroid cancer specimens suggests involvement of DNA-modifying APOBEC family enzymes [<xref rid="bib37" ref-type="bibr">37</xref>]. APOBEC family cytidine deaminases convert cytidine to uracil, coupled to activity of the base excision repair and DNA replication processes [<xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>]. We explored expression of <italic>APOBEC</italic> family genes in experimental samples under investigation for thyroid tumor type-specific patterns (<xref rid="fig13" ref-type="fig">Figure&#x000a0;13</xref>). Four genes showed tumor type-specific differential expression, which was increased in PC compared to FA and FC: <italic>APOBEC3C, APOBEC3F, APOBEC3G</italic>, and <italic>APOBEC4</italic> (<xref rid="fig13" ref-type="fig">Figure&#x000a0;13</xref>A). Furthermore, we also explored <italic>APOBEC</italic> family gene signature which was the sum of logarithmic expression levels of all family members under study: <italic>AICDA, APOBEC2, APOBEC3A, APOBEC3A_B, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4.</italic> The <italic>APOBEC</italic> signature was also differential for the comparisons of FA vs PC, and FC vs PC (<xref rid="fig13" ref-type="fig">Figure&#x000a0;13</xref>B). The direction of expression changes of <italic>APOBEC</italic> family gene signature and separate genes <italic>(APOBEC3C, APOBEC3F, APOBEC3G</italic>, and <italic>APOBEC4)</italic> coincides with direction of expression changes in DNA repair pathways (expression is higher in PC than in FC and FA).<fig id="fig13"><label>Figure&#x000a0;13</label><caption><p>(A) Boxplot representation of logarithmic expression of <italic>APOBEC</italic> genes in thyroid tumor types: FA (n = 17), FC (n = 23), PC (n = 51). q-value of Kruskel-Wallis test is shown. Asterisks (&#x02217;) indicate differential pairs of cancer types with Wilcoxon&#x02013;test p-value &#x0003c;0.05; double asterisks (&#x02217;&#x02217;) - with p-value &#x0003c;0.01. (B) <italic>APOBEC</italic> gene signature for three thyroid tumor types: FA (n = 17), FC (n = 23), PC (n = 51). Double asterisks (&#x02217;&#x02217;) denote pairs with p-value &#x0003c;0.01 by Wilcoxon&#x02013;test.</p></caption><alt-text id="alttext0115">Figure&#x000a0;13</alt-text><graphic xlink:href="gr13"/></fig></p></sec><sec id="sec2.6"><label>2.6</label><title>Gene expression pattern specific for radioactive iodine resistant tumors</title><p id="p0170">We then attempted to identify the radioiodine resistance (RAIR)-specific gene expression patterns using our experimental RNA sequencing dataset. To this end, we compared 13 RAIR samples with 62 thyroid cancer samples: 18 follicular cancers and 44 papillary cancers. We did not consider 17 samples of follicular adenoma and 3 samples of medullar cancer in this comparison. We found no statistically significant differences for all 38 DNA repair pathways, thus, we investigated expression on gene level. We selected 217 differentially regulated genes using Wilcoxon statistical test with Benjamini-Hochberg FDR-adjusted p-value&#x0003c;0.05. However, well known RAIR biomarker gene <italic>SLC5A5</italic> was not included in the list because it did not pass the FDR criterion. We, therefore, modified the candidate gene search criterion so that it would be maximally strict and at the same time would allow <italic>SLC5A5</italic> (p <italic>=</italic> 0.00344<italic>)</italic> to be selected. Thus, we marked as differential all the genes with Wilcoxon test p-value less than 0.0035.</p><p id="p0175">As a result, we identified 871 differential genes (Supplementary File 8) and then characterized partly their functional impacts using Gene Ontology (GO) analysis. Only 550 of these genes had functional GO annotation, and five statistically significantly enriched GO terms were identified in total (<xref rid="fig14" ref-type="fig">Figure&#x000a0;14</xref>). ClueGo [<xref rid="bib55" ref-type="bibr">55</xref>] software analysis showed that these terms belong to two functional groups.<fig id="fig14"><label>Figure&#x000a0;14</label><caption><p>Statistically significantly enriched gene ontology (GO) molecular processes (GO-terms) identified for 871 differential genes between radioiodine resistant cancers and other thyroid cancer samples. Differential gene names are shown in red. Circle size inversely reflects FDR-adjusted p-value for a differential GO-term identified. Filled part of a circle represents percentage share of matched differential genes in gene set of the respective GO-term. Links between the terms are taken from the STRING database.</p></caption><alt-text id="alttext0120">Figure&#x000a0;14</alt-text><graphic xlink:href="gr14"/></fig></p><p id="p0180">The first group deals with response to topologically incorrect (misfolded and unfolded) proteins. Unfolded protein response (UPR) is a cellular process related to the endoplasmic reticulum (ER) stress [<xref rid="bib56" ref-type="bibr">56</xref>]. The information about the protein folding status is sensed in the ER lumen and transmitted to the cytoplasm and the nucleus. UPR signaling pathway includes transcriptional induction of UPR genes, global attenuation of translation, and ER-associated protein degradation. If the protein folding defect is not corrected, cells undergo apoptosis [<xref rid="bib57" ref-type="bibr">57</xref>]. We found no previous references in the scientific literature to the association between the response to unfolded proteins and radioiodine resistance in thyroid cancer. However, induction of UPR was reported to promote radiosensibilization in radioresistant colorectal cancer cells [<xref rid="bib58" ref-type="bibr">58</xref>].</p><p id="p0185">The second functional group included only one GO term: aldo-keto reductase (NADP) activity. The aldo-keto reductase (AKR) superfamily comprises several enzymes that catalyze redox transformations involved in biosynthesis, intermediary metabolism, and detoxification [<xref rid="bib59" ref-type="bibr">59</xref>]. We found no publications linking AKRs with radioiodine resistance of thyroid cancer. However, it was previously reported that small interfering RNA specific to <italic>AKR1C3</italic> gene could significantly enhance sensitivity to radiation therapy in non-small cell lung cancer cells [<xref rid="bib53" ref-type="bibr">53</xref>]. In contrast, overexpression of <italic>AKR1C3</italic> also increased radioresistance of prostate and esophageal cancer cells [<xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib60" ref-type="bibr">60</xref>]. Meanwhile, increased aldehyde reductase expression mediates acquired radioresistance of laryngeal cancer via p53-related mechanism [<xref rid="bib61" ref-type="bibr">61</xref>].</p><p id="p0190a">In addition, five differential genes out of 871 identified belonged to the DNA repair pathways (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>). One of them (<italic>GTF2H2C)</italic> is involved in nucleotide excision repair and RNA transcription [<xref rid="bib62" ref-type="bibr">62</xref>]. For the other four genes, a link to radiation therapy was previously mentioned in the literature.<table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>DNA repair genes linked with the radioiodine resistant thyroid cancer samples.</p></caption><alt-text id="alttext0165">Table&#x000a0;3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Gene ID</th><th>Gene function according to GeneCards database [<xref rid="bib62" ref-type="bibr">62</xref>]</th><th>Relevant DNA repair pathways</th></tr></thead><tbody><tr><td><italic>CDC42</italic></td><td><italic>CDC42</italic> encodes a small GTPase of the Rho subfamily that regulates signaling pathways controlling cell morphology, migration, endocytosis, and cell cycle progression.</td><td>&#x02022; p53 Signaling Pathway</td></tr><tr><td><italic>GTF2H2C</italic></td><td>Component of the core-TFIIH basal transcription factor involved in nucleotide excision repair of DNA and, when complexed to CDK activating kinase, in RNA transcription by RNA polymerase II.</td><td>&#x02022; KEGG Nucleotide excision repair pathwayp2p<break/>&#x02022; Reactome Formation of transcription coupled NER TC NER repair complex pathway</td></tr><tr><td><italic>RFC5</italic></td><td><italic>RFC5</italic> encodes the smallest subunit of the factor C complex required for DNA replication. This subunit interacts with the C-terminus of PCNA protein and loads it onto DNA during S-phase of the cell cycle. <italic>RFC5</italic> is a member of the AAA+ (ATPases associated with various cellular activities) family and forms a core complex with the other two subunits that possesses DNA-dependent ATPase activity.</td><td>&#x02022; Mismatch Repair in Eukaryotes Pathway,<break/>&#x02022; KEGG Mismatch repair pathway,<break/>&#x02022; KEGG Nucleotide excision repair pathway,<break/>&#x02022; NCI ATR signaling Pathway regulation of double strand break repair via homologous recombination,<break/>&#x02022; NCI ATR signaling Pathway negative regulation of transcription during mitosis via CHEK1,<break/>&#x02022; NCI ATR signaling Pathway response to G2 M transition DNA damage checkpoint signal,<break/>&#x02022; Reactome Repair synthesis for gap filling by DNA polymerase in TC NER pathway,<break/>&#x02022; NCI ATR signaling pathway,<break/>&#x02022; NCI Fanconi anemia pathway<break/>&#x02022; NCI Fanconi anemia pathway (Sister Chromatid Exchange Process)<break/>&#x02022; NCI Fanconi anemia pathway (regulation of double strand break repair via homologous recombination)</td></tr><tr><td><italic>RBX1</italic></td><td><italic>RBX1</italic> encodes a RING finger-like domain-containing protein that interacts with cullin proteins and likely plays a role in ubiquitination processes necessary for cell cycle progression and DNA repair.</td><td>&#x02022; KEGG Nucleotide excision repair pathway</td></tr><tr><td><italic>RPS27A</italic></td><td>Ubiquitin has a major role in targeting cellular proteins for proteasomal degradation, is synthesized as a precursor protein consisting of either polyubiquitin chains or a single ubiquitin fused to an unrelated protein. <italic>RPS27A</italic> encodes a fusion protein consisting of ubiquitin at the N terminus and ribosomal protein S27a at the C terminus.</td><td>&#x02022; reactome Fanconi Anemia pathway</td></tr></tbody></table></table-wrap></p><p id="p0195"><italic>RFC5</italic> gene product is part of the Rad17-RFC complex, which is one of the mechanisms of cellular recognition of a radiation insult [<xref rid="bib63" ref-type="bibr">63</xref>]. The complex can dock on fractured DNA or near the site of damaged DNA and initiate downstream signaling, including activation of ATM and ATR kinases [<xref rid="bib63" ref-type="bibr">63</xref>]. Then the ATM and ATR signaling pathways activate downstream effectors and thus regulate cell cycle arrest, DNA repair, and apoptosis [<xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref>, <xref rid="bib66" ref-type="bibr">66</xref>, <xref rid="bib67" ref-type="bibr">67</xref>].</p><p id="p0200">Cdc42 belongs to the Rho subfamily of GTPases, which plays a key role in the initiation and progression of cancer by transmitting oncogenic signals from the cell surface receptors and from activated guanine nucleotide exchange factors (GEF) signaling [<xref rid="bib62" ref-type="bibr">62</xref>]. Alternatively, Cdc42 can be activated by the PI3K signaling through activation of PIP3-regulated GEFs, such as P-Rex, Vav, Sos, and SWAP70 [<xref rid="bib68" ref-type="bibr">68</xref>]. Recently, Rac1 inhibition has been shown to sensitize pancreatic and breast cancer cells to radiation therapy, therefore, Rac and, similarly, Cdc42 may be regarded as the putative targets for chemosensitization of radiotherapy [<xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref>, <xref rid="bib71" ref-type="bibr">71</xref>].</p><p id="p0205">RBX1 contributes to the G1 phase-specific degradation of Exonuclease 1 (EXO1), which is responsible for the protruding 3&#x02032; single stranded DNA formation during processing of double-strand breaks. RBX1 knockdown decreases the degradation of EXO1 [<xref rid="bib72" ref-type="bibr">72</xref>], and its depletion causes radiosensibilization of cervical cancer cells and deficiency in DNA double-strand breaks repair [<xref rid="bib72" ref-type="bibr">72</xref>]. <italic>RBX1</italic> silencing significantly sensitizes radioresistant glioblastoma and lung cancer cells to the radiation with sensitivity enhancement ratios of 1.5 and 1.3, respectively [<xref rid="bib73" ref-type="bibr">73</xref>].</p><p id="p0210">Finally, the <italic>RPS27A</italic> gene was reported to be over-expressed in breast fibroadenomas, colorectal, renal cancers, chronic myeloid leukemia and acute leukemia [<xref rid="bib74" ref-type="bibr">74</xref>, <xref rid="bib75" ref-type="bibr">75</xref>, <xref rid="bib76" ref-type="bibr">76</xref>]. Ubiquitin is encoded by four different genes that are highly homologous in eukaryotes. <italic>UBA52</italic> and <italic>RPS27A</italic> genes code for a single copy of ubiquitin fused to the ribosomal proteins L40 and S27a, respectively. Knock-down of ubiquitin increased the radiosensitivity in H1299 cells, thus <italic>RPS27A</italic> may contribute to radioresistance of tumor cells [<xref rid="bib77" ref-type="bibr">77</xref>].</p></sec><sec id="sec2.7"><label>2.7</label><title>Fusion gene transcripts</title><p id="p0215">We screened RNA sequencing reads for the clinically relevant hybrid transcripts with eleven oncogenes: <italic>ALK, ROS1, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BCR,</italic> and <italic>ABL1</italic>. We found reads directly supporting two fusion transcripts with genes <italic>ALK</italic> and <italic>RET</italic>. One was in-frame fusion for well-known <italic>NCOA4-RET</italic> translocation [107] (<xref rid="fig15" ref-type="fig">Figure&#x000a0;15</xref>A), and another one was frameshift fusion of <italic>ALK</italic> oncogene with a previously unknown upstream partner <italic>ARHGAP12</italic> (<xref rid="fig16" ref-type="fig">Figure&#x000a0;16</xref>A). Seventh exon of <italic>NCOA4</italic> was fused with the eleventh exon of <italic>RET</italic>. In turn, third exon of <italic>ARHGAP12</italic> was fused with the fourth exon of <italic>ALK</italic>. In both cases, exon coverage also supported fusion status for the <italic>ALK</italic> (<xref rid="fig16" ref-type="fig">Figure&#x000a0;16</xref>B) and <italic>RET</italic> (<xref rid="fig15" ref-type="fig">Figure&#x000a0;15</xref>B) genes as the relative coverage downstream to the fusion site was higher than upstream (Figures&#x000a0;<xref rid="fig6" ref-type="fig">6</xref>B, <xref rid="fig7" ref-type="fig">7</xref>B).<fig id="fig15"><label>Figure&#x000a0;15</label><caption><p>Schematic representation of <italic>NCOA4-RET</italic> fusion transcript identified. <italic>A</italic>, gene structures upstream and downstream of fusion site. <italic>B</italic>, <italic>RET</italic> gene exon coverage by normalized RNA sequencing reads in RAIR4 sample.</p></caption><alt-text id="alttext0125">Figure&#x000a0;15</alt-text><graphic xlink:href="gr15"/></fig><fig id="fig16"><label>Figure&#x000a0;16</label><caption><p>Schematic representation of <italic>ARHGAP1</italic>2-ALK fusion transcript identified. (A) gene structures upstream and downstream of fusion site. (B) <italic>ALK</italic> gene exon coverage by normalized RNA sequencing reads in TC12 sample.</p></caption><alt-text id="alttext0130">Figure&#x000a0;16</alt-text><graphic xlink:href="gr16"/></fig></p><p id="p0220">Both fusions were found in papillary thyroid cancers of follicular histologic subtype with node metastases, one of them (<italic>NCOA4-RET</italic>) in the radioactive iodine resistant tumor. We didn't detect any outstanding DNA repair pathway activation features in the samples with fusion transcripts (<xref rid="fig17" ref-type="fig">Figure&#x000a0;17</xref>).<fig id="fig17"><label>Figure&#x000a0;17</label><caption><p>PAL distribution for 38 DNA repair pathways in experimental thyroid tumor samples. Color denotes samples with gene fusions. Pathway name abbreviations: p1 - ATM Pathway, p2 - ATM Pathway Cell Survival, p3 - ATM Pathway G2-Mitosis progression, p4 - Biocarta atm signaling pathway, p5 - Biocarta cell cycle G2M checkpoint pathway, p6 - BRCA1 Pathway, p7 - BRCA1 Pathway Chromatin Remodeling, p8 - BRCA1 Pathway Homologous Recombination Repair, p9 - BRCA1 Pathway Mismatch Repair, p10 - DNA Repair Mechanisms Pathway, p11 - KEGG Base excision repair pathway, p12 - KEGG Fanconi anemia pathway, p13 - KEGG Homologous recombination pathway, p14 - KEGG Mismatch repair pathway, p15 - KEGG Non homologous end joining pathway, p16 - KEGG Nucleotide excision repair pathway, p17 - Mismatch Repair in Eukaryotes Pathway, p18 - NCI ATM pathway, p19 - NCI ATM Pathway (G1 S transition checkpoint), p20 - NCI ATR signaling pathway, p21 - NCI ATR signaling Pathway (Pathway negative regulation of transcription during mitosis via CHEK1), p22 - NCI ATR signaling Pathway (regulation of double strand break repair via homologous recombination), p23 - NCI ATR signaling Pathway (response to G2 M transition DNA damage checkpoint signal), p24 - NCI DNA PK pathway in nonhomologous end joining Pathway (double strand break repair via nonhomologous end joining), p25 - NCI DNA PK pathway in nonhomologous end joining Pathway (V D J recombination), p26 - NCI Fanconi anemia pathway, p27 - NCI Fanconi anemia Pathway (regulation of double strand break repair via homologous recombination), p28 - NCI Fanconi anemia Pathway (Sister Chromatid Exchange Process), p29 - NHEJ mechanisms of DSBs repair effect, p30 - Nucleotide excision repair effect, p31 - p53 Signaling Pathway, p32 - p53 Signaling Pathway DNA Repair, p33 - p53 Signaling Pathway Gene Expression DNA Replication and Repair via TP53, p34 - reactome Fanconi Anemia pathway, p35 - Reactome Formation of transcription coupled NER TC NER repair complex pathway, p36 - Reactome Mismatch repair MMR directed by MSH2, MSH3, MutS beta pathway, p37 - Reactome Mismatch repair MMR directed by MSH2, MSH6, MutS alpha pathway, p38 - Reactome Repair synthesis for gap filling by DNA polymerase in TC NER pathway.</p></caption><alt-text id="alttext0135">Figure&#x000a0;17</alt-text><graphic xlink:href="gr17"/></fig></p></sec></sec><sec id="sec3"><label>3</label><title>Discussion</title><p id="p0225">Here we present clinically annotated RNA sequencing data for 95 human thyroid tumor biosamples corresponding to 17 follicular adenomas, 23 follicular, 51 papillary, 1 poorly differentiated, and 3 medullar thyroid cancers cases. These molecular data are fully compatible with the previously published ANTE database, which includes RNA sequencing profiles for healthy human tissues, including thyroid tissue [<xref rid="bib45" ref-type="bibr">45</xref>]. The gene expression dataset is assembled in a machine-readable format and annotated by the available patients&#x02019; data, including type and histological subtype of thyroid tumor, sex, age, diagnosis, and <italic>BRAF</italic> (V600E) mutation status and gene fusion status. This dataset will hopefully be useful to those interested in thyroid tumor biology, especially in the context of relevant data accumulation from different sources. The use of this material in further analytic investigations can make it possible to identify and validate thyroid tumor type-specific expression biomarkers.</p><p id="p0230">These data allowed us to analyze characteristic features of DNA repair pathway regulation in different thyroid tumor types. Follicular and papillary cancers demonstrated higher activation level of DNA repair pathways than the follicular adenomas. Our results suggest that papillary cancers have more activated DNA repair pathways than follicular neoplasms, with the remarkable exception of a G2M transition checkpoint pathway which showed an opposite trend. We found that most of DNA repair pathways were minimally activated (among tumors) in follicular adenomas. This trend was also confirmed for literature dataset PRJEB11591. We hypothesize that lower DNA repair pathway activation strengths in follicular adenomas compared to thyroid tumors can be linked with relatively lower level of DNA replication defects. Alternatively, this effect can be also connected with hypoxia which frequently accompanies benign tumors and inhibits DNA repair pathways [<xref rid="bib78" ref-type="bibr">78</xref>].</p><p id="p0235">Thus, our results demonstrate that DNA repair activity is increased in malignant compared to benign tumors. The same trend was also established for the tumor-adjacent pathologically normal tissues. These two evidences highlight the link between tumor progression and increased level of DNA repair and are consistent with the previous literature data on DNA repair in thyroid tumors [<xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib79" ref-type="bibr">79</xref>]. In agreement with that, the increased level of DNA damage marker 8-oxo-dG had been previously reported for thyroid tumors [<xref rid="bib80" ref-type="bibr">80</xref>]. The same trend was also observed for another reactive oxygen marker, cytoplasmic 4-HNE, which characterizes lipid peroxidation level [<xref rid="bib80" ref-type="bibr">80</xref>].</p><p id="p0240">We also reconstructed DNA repair networks that were differential in the FC versus PC, FC + PC versus FA, and PC versus FA comparisons, and identified statistically significantly differential nodes. It is of note that the differential gene lists were very similar in these three comparisons. This fact may suggest that molecular differences between the follicular and papillary neoplasms are bigger than between the malignant and benign tumors.</p><p id="p0245">In this study we identified statistically differential features of DNA repair pathway activation between follicular and papillary thyroid cancers. Uncovering these differences may not only contribute to understanding of molecular mechanisms of thyroid tumors but also may help further developing new molecular-based therapeutic approaches for different types and subtypes of TCs. DNA repair has dual significance by simultaneously slowing down tumor evolution but also by protecting tumor cells from the treatment of replication targeting therapeutics. Thus, controlled inhibition of DNA repair activities can be considered personalized therapeutic option [<xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>]. On the other hand, we found no differential DNA repair pathways between radioiodine resistant and sensitive tumor samples. This may suggest that the molecular differences between thyroid tumor types are more significant than differences between radioiodine resistant and sensitive tumors.</p><p id="p0250">Another key point of this study deals with the expression patterns of tumor-adjacent pathologically normal tissues learned from the literature dataset PRJEB11591. We showed that activation levels of DNA repair pathways strongly correlated between the tumor and adjacent normal tissues (R Pearson = 0.8492, p-value &#x0003c; 2.2e-16, <xref rid="fig12" ref-type="fig">Figure&#x000a0;12</xref>B). This observation is consistent with some previous studies [<xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>] and suggests that tumor-adjacent pathologically normal tissues can be strongly affected by the tumor and must be considered with care when comparing cancerous and healthy tissues.</p><p id="p0255">Annotations for 23 molecular profiles published here include the response data on radioactive iodine therapy, of them 10 were for the treatment responders and 13 for the non-responders. This sampling is modest in terms of robust biomarker discovery. However, these datasets can be combined with the previously published or future data collections <italic>e.g.</italic> using harmonization of gene expression profiles data formats [<xref rid="bib85" ref-type="bibr">85</xref>]. Alternatively, advanced methods of reducing data dimensionality can be applied in order to make use of machine learning and other artificial intelligence approaches to further analyze the data [<xref rid="bib86" ref-type="bibr">86</xref>, <xref rid="bib87" ref-type="bibr">87</xref>, <xref rid="bib88" ref-type="bibr">88</xref>].</p><p id="p0260">Finally, we identified fusion transcripts for <italic>ALK</italic> and <italic>RET</italic> oncogenes. One of them represents a well-known <italic>NCOA4-RET</italic> translocation, and another one is a new hybrid transcript of <italic>ALK</italic> oncogene with a previously unknown upstream fusion partner <italic>ARHGAP12</italic>. The latter can probably drive increased transcription of truncated <italic>ALK</italic> downstream from the fusion site because its normalized expression is one-two orders of magnitude higher in the normal tissues than for the <italic>ALK</italic> gene (UCSC Genome Browser, <ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu" id="intref0010">https://genome.ucsc.edu</ext-link>). This was also the case for our experimental dataset of thyroid tumor tissues, where mean normalized <italic>ARHGAP12</italic> expression was ~12-fold greater than the expression of <italic>ALK</italic>.</p><p id="p0265">We hope that the data communicated here could be used for fundamental cancer research applications and for revising lists of tumor specific gene expression biomarkers, including those that distinguish between malignant and benign thyroid tumors and predict response to iodine radiation therapy.</p></sec><sec id="sec4"><label>4</label><title>Materials and methods</title><sec id="sec4.1"><label>4.1</label><title>Biosamples</title><p id="p0270">Biosamples were obtained from patients diagnosed with primary thyroid tumors who had undergone surgery at Endocrinology Research Centre, Moscow. For all the biosamples, informed written consents to participate in the study were collected from the patients or their legal representatives. The study was conducted in accordance with the Declaration of Helsinki ethical principles. The consent procedure and the design of the study were approved by the local ethical committee of the Endocrinology Research Centre, Moscow, protocol number 19 (October 25, 2017, Chairman Dr. E.N. Andreeva). From the patients TC16, TC18, TC19, TC26 and TC127, the consent was obtained for disclosure of sex, histological tumor type, and molecular data including RNA sequencing data but excluding whole-genome and/or whole-exome sequencing data; from the patients TC11, TC12, TC17, TC37 and TC125 - for disclosure of sex, histological tumor type, diagnosis, and molecular data including RNA sequencing data but excluding whole-genome and/or whole-exome sequencing data; for the rest of the patients - for disclosure of sex, age, histological tumor type, diagnosis, and molecular data including RNA sequencing data but excluding whole-genome and/or whole-exome sequencing data.</p><p id="p0275">Tissue specimens were formalin-fixed and embedded in paraffin. Tumors were evaluated by a pathologist to determine histological type and to estimate proportion of tumor cells. All the specimens used in this study contained at least 60% of tumor cells.</p><p id="p0280">Overall, 51 papillary thyroid cancer (PC), 23 follicular thyroid cancer (FC), 3 medullary thyroid cancer (MC), 1 poorly differentiated thyroid cancer (PDC), and 17 follicular thyroid adenoma (FA) samples were investigated. There were 21 male and 74 female patients. The mean age of patients was 47 years (range 11&#x02013;88 years). Additionally, 6 healthy thyroid tissue samples from ANTE database [<xref rid="bib45" ref-type="bibr">45</xref>] were used to normalize gene expression levels in molecular pathway analysis. Clinical annotations of tumor specimens investigated are summarized in the Supplementary file 1.</p></sec><sec id="sec4.2"><label>4.2</label><title>RNA sequencing</title><p id="p0285">RNA libraries were generated, sequenced, and processed as described in [<xref rid="bib45" ref-type="bibr">45</xref>]. RNA extraction was performed with the RecoverAll&#x02122; Total Nucleic Acid Isolation Kit (Invitrogen), following the manufacturer's protocol. RNA Integrity Number (RIN) was measured using Agilent 2100 bioanalyzer. RNA concentration was measured with Agilent RNA 6000 Nano or Qubit RNA Assay Kits. Depletion of ribosomal RNA was performed using RNA Hyper with RiboErase (KAPA Biosystem) Kit. Library concentrations and quality were measured with Qubit ds DNA HS Assay kit (Life Technologies) and Agilent Tapestation (Agilent). The samples were sequenced using Illumina HiSeq 3000 equipment for single end sequencing, 50&#x02009;bp read length, for approximately 30 million raw reads per sample. Data quality check was conducted using Illumina SAV. De-multiplexing was performed using Illumina Bcl2fastq2 v 2.17 software [<xref rid="bib45" ref-type="bibr">45</xref>].</p></sec><sec id="sec4.3"><label>4.3</label><title>Processing of RNA sequencing data</title><p id="p0290">RNA sequencing FASTQ files were processed with STAR aligner [<xref rid="bib89" ref-type="bibr">89</xref>]. We used &#x02018;GeneCounts&#x02019; mode with the Ensembl human transcriptome annotation (Build version GRCh38 and transcript annotation GRCh38.89). Complete HGNC dataset [<xref rid="bib90" ref-type="bibr">90</xref>], version of July 13, 2017, was used to convert Ensembl gene IDs to HGNC gene symbols.</p></sec><sec id="sec4.4"><label>4.4</label><title>Evaluation of BRAF (V600E) mutation status</title><p id="p0295">Detection of <italic>BRAF</italic> (V600E) mutation was performed using allele-specific PCR with dual-labeled probe as described in [<xref rid="bib91" ref-type="bibr">91</xref>]. PCR cycling conditions were pre-denaturation step 95&#x000b0;&#x00421; &#x02013; 2 min, followed by 50 cycles of denaturation (94&#x000b0;&#x00421;, 10 s), annealing, and elongation (60&#x000b0;&#x00421;, 15 s). Mutation status was considered positive if the mutant allele content was 3% or more of the wild-type allele.</p></sec><sec id="sec4.5"><label>4.5</label><title>Histological characterization of samples</title><p id="p0300">All samples were subjected to histological analysis, representative microphotographs of preparations of the thyroid tumor types investigated are shown in <xref rid="fig18" ref-type="fig">Figure&#x000a0;18</xref>.<fig id="fig18"><label>Figure&#x000a0;18</label><caption><p>Representative microphotographs of eosin-hematoxylin stained histology preparations of different thyroid tumor types. A &#x02013; papillary thyroid cancer (TC), magnification X200, sample ID: TC_65; B - Follicular thyroid cancer (FC), magnification X50, sample ID: TC_119; C &#x02013; Follicular adenoma (FA), magnification X100, sample ID: TC_22; D &#x02013; medullary thyroid cancer (MC), magnification X50, sample ID: TC_17.</p></caption><alt-text id="alttext0140">Figure&#x000a0;18</alt-text><graphic xlink:href="gr18"/></fig></p><p id="p0305">Specific histology subtypes of the specimens are given in the Supplementary file 1. For further analyses, we grouped specimens by major tumor types: PC, FC, MC, and FA.</p></sec><sec id="sec4.6"><label>4.6</label><title>Quality control of mRNA sequencing profiles</title><p id="p0310">Detailed annotation of RNA sequencing reads mapping statistic produced by STAR aligner [<xref rid="bib89" ref-type="bibr">89</xref>] and quality control metrics produced by NCBI MAGIC software [<xref rid="bib79" ref-type="bibr">79</xref>] are shown in the Supplementary file 2. Minimal number of reads uniquely mapped on mRNA sequences of known genes was ~3,4&#x02217;10<sup>6</sup> with the mean of ~9,2&#x02217;10<sup>6</sup> (Supplementary file 2). Average mapping rate, taking into account only uniquely mapped reads, was 78%. Typical per base and per sequence quality scores visualized by fastQC software [<xref rid="bib80" ref-type="bibr">80</xref>] demonstrated high values for individual base pairs and read sequences (<xref rid="fig19" ref-type="fig">Figure&#x000a0;19</xref> A, B).<fig id="fig19"><label>Figure&#x000a0;19</label><caption><p>Quality control of RNA sequencing profiles. A - fastQC per base quality score for sample TC76. The plot was drawn using fastQC software. B - fastQC per sequence quality score for sample TC76. The plot was drawn using fastQC software. C - plot for principal component analysis in normalized gene expression space (lg(RPM)) for all RNA sequencing profiles investigated. The plot was drawn using graphics package in R language. D - hierarchical clustering of all RNA sequencing profiles based on Euclidian distance in normalized gene expression space (lg(RPM)). The plot was drawn using pheatmap package in R, clustering algorithm &#x0201c;ward.d2&#x0201d;.</p></caption><alt-text id="alttext0145">Figure&#x000a0;19</alt-text><graphic xlink:href="gr19"/></fig></p><p id="p0315">Principal component analysis (PCA) and hierarchical clustering based on Euclidian distance in normalized counts (lg(RPM)) space did not reveal any outliers (<xref rid="fig19" ref-type="fig">Figure&#x000a0;19</xref> C, D). In comparison with other FC and PC samples, three FC samples formed a distant cluster (TC2, TC4, TC124; <xref rid="fig19" ref-type="fig">Figure&#x000a0;19</xref>C, circled). These three cluster members had 150 differentially expressed genes with q-value&#x0003c;0.05 by Wilcoxon test (Supplementary File 9). The gene contribution coefficients for the first two principal components are given in Supplementary File 9.</p><p id="p0320">We performed sequencing of two technical replicates of samples TC63 and TC116, Spearman's correlation coefficient between gene expression profiles was 0.95 for both cases. We also found that the replicates tightly clustered on the dendrogram (<xref rid="fig20" ref-type="fig">Figure&#x000a0;20</xref>) which confirmed data consistency of the RNA sequencing protocol used.<fig id="fig20"><label>Figure&#x000a0;20</label><caption><p>Comparison of RNA sequencing gene expression profiles of two technical replicates: for TC-63 sample <italic>(A)</italic>, and for TC-116 sample (<italic>B</italic>). Clustering dendrogram of experimental tumor samples expression profiles (<italic>C</italic>), technical replicates are shown in color.</p></caption><alt-text id="alttext0150">Figure&#x000a0;20</alt-text><graphic xlink:href="gr20"/></fig></p><p id="p0325">Overall, our data quality assay did not identify any significant internal problems or internal bias in the RNA sequencing data presented. We did not include the poorly differentiated thyroid cancer sample in our further analysis because it cannot be used for group comparisons. We used reads per million (RPM) normalization of expression data. We filtered low-expressed values (less than one) to reduce data noise.</p></sec><sec id="sec4.7"><label>4.7</label><title>Data records</title><p id="p0330">Original gene expression data were deposited in Gene Expression Omnibus database (GEO) under accession number GSE138042. Raw fastq data are available in SRA archive under accession number PRJNA588725. Description of clinically relevant (age, sex, diagnosis, tumor histotype, <italic>BRAF</italic> (V600E) mutation status) and technical (RIN, date of sequencing) information is given in the Supplementary file 1. Results of RNA sequencing reads quality assay are given for mRNA in the Supplementary file 2.</p></sec><sec id="sec4.8"><label>4.8</label><title>Structures of DNA repair pathways</title><p id="p0335">The gene structures and molecular architectures of 38 DNA repair pathways were obtained from the public databases Reactome [<xref rid="bib40" ref-type="bibr">40</xref>], NCI Pathway Interaction Database [<xref rid="bib41" ref-type="bibr">41</xref>], Kyoto Encyclopedia of Genes and Genomes [<xref rid="bib42" ref-type="bibr">42</xref>], Biocarta [<xref rid="bib43" ref-type="bibr">43</xref>], and Qiagen [<xref rid="bib44" ref-type="bibr">44</xref>], and manually curated as described in [<xref rid="bib81" ref-type="bibr">81</xref>]. Only molecular pathways which include ten or more genes [<xref rid="bib82" ref-type="bibr">82</xref>] were considered in calculations of pathway activation level (PAL) in order to increase statistical accuracy.</p></sec><sec id="sec4.9"><label>4.9</label><title>Alternative thyroid tissue datasets</title><p id="p0340">We used published RNA sequencing gene expression profiles of normal thyroid tissues from TCGA [<xref rid="bib83" ref-type="bibr">83</xref>] and GTEx [<xref rid="bib84" ref-type="bibr">84</xref>] project databases, amounting to 58 and 446 profiles, correspondingly. Samples barcodes are shown in Supplementary File 6. Raw gene counts were processed as reads per million (RPM).</p><p id="p0345">Alternatively, thyroid tumor and normal thyroid RNA sequencing profiles from dataset PRJEB11591 [<xref rid="bib92" ref-type="bibr">92</xref>,<xref rid="bib93" ref-type="bibr">93</xref>] were used. The dataset includes data for 25 FA, 30 minimally invasive FC, 48 follicular variant of PC (FV), 77 classical papillary thyroid carcinomas (PC) and 81 adjacent normal thyroid tissues. FASTQ files were processed by STAR aligner [<xref rid="bib89" ref-type="bibr">89</xref>] to get raw gene counts that were processed as RPM.</p><p id="p0350">The proteome datasets from CPTAC [<xref rid="bib94" ref-type="bibr">94</xref>] and corresponding transcriptome datasets from gdc-portal [<xref rid="bib29" ref-type="bibr">29</xref>] were used to assess correlation between expression on transcriptome and proteome level for key genes in tumor and normal tissues. We totally used 102 paired RNA sequencing and proteome profiles of breast, 53 - colon, 210 &#x02013; lung, 108 &#x02013; brain, 62 &#x02013; ovary, 151 &#x02013; head and neck tissues.</p></sec><sec id="sec4.10"><label>4.10</label><title>Calculation of pathway activation level</title><p id="p0355">Pathway activation level (PAL) characterizes cumulative changes in expression levels of genes belonging to a certain molecular pathway [<xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib95" ref-type="bibr">95</xref>]. PAL is calculated as follows:<disp-formula id="ufd1"><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mi>P</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>L</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:munder><mml:mrow><mml:mo>&#x02211;</mml:mo></mml:mrow><mml:mi>n</mml:mi></mml:munder><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#x02217;</mml:mo><mml:mtext>lg</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:mi>N</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo linebreak="goodbreak">/</mml:mo><mml:munder><mml:mrow><mml:mo>&#x02211;</mml:mo></mml:mrow><mml:mi>n</mml:mi></mml:munder><mml:mrow><mml:mo stretchy="false">|</mml:mo><mml:mi>A</mml:mi><mml:mi>R</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <italic>PAL</italic><sub><italic>p</italic></sub> is PAL for pathway p, CNRn is case-to-normal ratio, the ratio of gene n expression level in a tumor sample under study to an average level in the control group; ARR (activator/repressor role) is a Boolean flag that depends on the function of gene <italic>n</italic> product in pathway <italic>p</italic>. ARR value is &#x02212;1 if gene product n inhibits pathway p; 1 if n activates the pathway; 0 if n has ambiguous or unclear role in the pathway; 0.5 or &#x02212;0.5, if n is more a pathway activator or its inhibitor, respectively. For convenience, in this article we use modified PAL = PAL&#x02217;100. PAL values for all samples under investigation are given in Supplementary File 6.</p></sec><sec id="sec4.11"><label>4.11</label><title>Gene ontology analysis and visualization of molecular pathways</title><p id="p0360">Gene Ontology (GO) analysis was performed using ClueGO software [<xref rid="bib55" ref-type="bibr">55</xref>] with GO database from 28.04.2020. GO-analysis results and molecular pathways were visualized using Cytoscape 3.8.0 [<xref rid="bib96" ref-type="bibr">96</xref>].</p></sec><sec id="sec4.12"><label>4.12</label><title>Identification of fusion transcripts</title><p id="p0365">Fusion transcripts were initially screened using STAR-Fusion software. Preliminary files containing fusion candidates for genes <italic>ALK, ROS1, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BCR, ABL1</italic> were generated and the corresponding RNA sequencing reads were extracted. The output data were manually inspected using UCSC BLAT and UCSC Browser (<ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu/" id="intref0015">https://genome.ucsc.edu/</ext-link>) to interrogate fusion candidates according to the following criteria: (i) does the read cover exon junction of two different transcripts, (ii) if the junction point exactly corresponds to exon termini of known genes with canonic splice sites, (iii) if both transcripts are in the same orientation. The inputs with three positive flags were considered as those supporting fusion transcripts.</p></sec></sec><sec id="sec5"><title>Declarations</title><sec id="sec5.1"><title>Author contribution statement</title><p id="p0370">Anton Buzdin, Maxim Sorokin: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.</p><p id="p0375">Uliana Vladimirova: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Wrote the paper.</p><p id="p0380">Pavel Rumiantsev, Dmitriy Kamashev: Conceived and designed the experiments; Analyzed and interpreted the data.</p><p id="p0385">Marianna Arsenovna Zolotovskaia: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.</p><p id="p0390">Eugene Albert: Analyzed and interpreted the data; Wrote the paper.</p><p id="p0395">Aleksander Abrosimov: Performed the experiments.</p><p id="p0400">Konstantin Slashchuk, Petr Nikiforovich, Olga Chukhacheva: Contributed reagents, materials, analysis tools or data.</p><p id="p0406">Nurshat Gaifullin: Conceived and designed the experiments; Wrote the paper.</p><p id="p0405">Maria Suntsova, Xinmin Li: Conceived and designed the experiments; Performed the experiments.</p><p id="p0410">Galina Zakharova, Andrew Garazha: Analyzed and interpreted the data.</p><p id="p0415">Alexander Glusker: Conceived and designed the experiments.</p><p id="p0420">Daniil Nikitin: Analyzed and interpreted the data; Wrote the paper.</p><p id="p0425">Alexei Drobyshev, Irina Kochergina-Nikitskaya: Performed the experiments; Analyzed and interpreted the data.</p></sec><sec id="sec5.2"><title>Funding statement</title><p id="p0430">This work was supported by Omicsway Corp., USA, and by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002261</institution-id><institution>Russian Foundation for Basic Research</institution></institution-wrap></funding-source> grant (19-29-01108).</p></sec><sec sec-type="data-availability" id="sec5.3"><title>Data availability statement</title><p id="p0435">Data associated with this study has been deposited at GEO and SRA repositories and published under GEO accession id <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE138042" id="intref0020">GSE138042</ext-link>.</p></sec><sec sec-type="COI-statement" id="sec5.4"><title>Declaration of interests statement</title><p id="p0440">The authors declare no conflict of interest.</p></sec><sec id="sec5.5"><title>Additional information</title><p id="p0445">No additional information is available for this paper.</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>La Vecchia</surname><given-names>C.</given-names></name><name><surname>Malvezzi</surname><given-names>M.</given-names></name><name><surname>Bosetti</surname><given-names>C.</given-names></name><name><surname>Garavello</surname><given-names>W.</given-names></name><name><surname>Bertuccio</surname><given-names>P.</given-names></name><name><surname>Levi</surname><given-names>F.</given-names></name><name><surname>Negri</surname><given-names>E.</given-names></name></person-group><article-title>Thyroid cancer mortality and incidence: a global overview</article-title><source>Int. J. Canc.</source><volume>136</volume><year>2015</year><fpage>2187</fpage><lpage>2195</lpage></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Cabanillas</surname><given-names>M.E.</given-names></name><name><surname>McFadden</surname><given-names>D.G.</given-names></name><name><surname>Durante</surname><given-names>C.</given-names></name></person-group><article-title>Thyroid cancer</article-title><source>Lancet</source><volume>388</volume><year>2016</year><fpage>2783</fpage><lpage>2795</lpage><pub-id pub-id-type="pmid">27240885</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Rahib</surname><given-names>L.</given-names></name><name><surname>Smith</surname><given-names>B.D.</given-names></name><name><surname>Aizenberg</surname><given-names>R.</given-names></name><name><surname>Rosenzweig</surname><given-names>A.B.</given-names></name><name><surname>Fleshman</surname><given-names>J.M.</given-names></name><name><surname>Matrisian</surname><given-names>L.M.</given-names></name></person-group><article-title>Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States</article-title><source>Canc. Res.</source><volume>74</volume><year>2014</year><fpage>2913</fpage><lpage>2921</lpage></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Asa</surname><given-names>S.L.</given-names></name></person-group><article-title>The current histologic classification of thyroid cancer</article-title><source>Endocrinol Metab. Clin. N. Am.</source><volume>48</volume><year>2019</year><fpage>1</fpage><lpage>22</lpage></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Younis</surname><given-names>E.</given-names></name></person-group><article-title>Oncogenesis of thyroid cancer</article-title><source>Asian Pac. J. Cancer Prev. APJCP</source><volume>18</volume><year>2017</year><fpage>1191</fpage><lpage>1199</lpage><pub-id pub-id-type="pmid">28610401</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Raue</surname><given-names>F.</given-names></name><name><surname>Frank-Raue</surname><given-names>K.</given-names></name></person-group><article-title>Epidemiology and clinical presentation of medullary thyroid carcinoma</article-title><source>Recent Results Canc. Res.</source><volume>204</volume><year>2015</year><fpage>61</fpage><lpage>90</lpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>de la Fouchardi&#x000e8;re</surname><given-names>C.</given-names></name><name><surname>Decaussin-Petrucci</surname><given-names>M.</given-names></name><name><surname>Berthiller</surname><given-names>J.</given-names></name><name><surname>Descotes</surname><given-names>F.</given-names></name><name><surname>Lopez</surname><given-names>J.</given-names></name><name><surname>Lifante</surname><given-names>J.C.</given-names></name><name><surname>Peix</surname><given-names>J.L.</given-names></name><name><surname>Giraudet</surname><given-names>A.L.</given-names></name><name><surname>Delahaye</surname><given-names>A.</given-names></name><name><surname>Masson</surname><given-names>S.</given-names></name><name><surname>Bournaud-Salinas</surname><given-names>C.</given-names></name><name><surname>Borson Chazot</surname><given-names>F.</given-names></name></person-group><article-title>Predictive factors of outcome in poorly differentiated thyroid carcinomas</article-title><source>Eur. J. Canc.</source><volume>92</volume><year>2018</year><fpage>40</fpage><lpage>47</lpage></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>E.Y.</given-names></name><name><surname>Busaidy</surname><given-names>N.L.</given-names></name></person-group><article-title>Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer</article-title><source>Curr. Opin. Oncol.</source><volume>29</volume><year>2017</year><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">28141684</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Shimura</surname><given-names>H.</given-names></name><name><surname>Haraguchi</surname><given-names>K.</given-names></name><name><surname>Miyazaki</surname><given-names>A.</given-names></name><name><surname>Endo</surname><given-names>T.</given-names></name><name><surname>Onaya</surname><given-names>T.</given-names></name></person-group><article-title>Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene</article-title><source>Endocrinology</source><volume>138</volume><year>1997</year><fpage>4493</fpage><lpage>4496</lpage><pub-id pub-id-type="pmid">9322970</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>B.</given-names></name><name><surname>Liao</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical, pathological, and molecular characteristics correlating to the occurrence of radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis</article-title><source>Front. Oncol.</source><volume>10</volume><year>2020</year><fpage>549882</fpage><pub-id pub-id-type="pmid">33117686</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Xing</surname><given-names>M.</given-names></name></person-group><article-title>The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer</article-title><source>J.&#x000a0;Nucl. Med.</source><volume>61</volume><year>2020</year><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">31375570</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name></person-group><article-title>TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer</article-title><source>J.&#x000a0;Nucl. Med.</source><volume>58</volume><year>2017</year><fpage>258</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">27493271</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Aashiq</surname><given-names>M.</given-names></name><name><surname>Silverman</surname><given-names>D.A.</given-names></name><name><surname>Na&#x02019;ara</surname><given-names>S.</given-names></name><name><surname>Takahashi</surname><given-names>H.</given-names></name><name><surname>Amit</surname><given-names>M.</given-names></name></person-group><article-title>Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies</article-title><source>Cancers</source><volume>11</volume><year>2019</year><fpage>1382</fpage></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Sarhan</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>B.C.</given-names></name><name><surname>Muendlein</surname><given-names>H.I.</given-names></name><name><surname>Weindel</surname><given-names>C.G.</given-names></name><name><surname>Smirnova</surname><given-names>I.</given-names></name><name><surname>Tang</surname><given-names>A.Y.</given-names></name><name><surname>Ilyukha</surname><given-names>V.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name><name><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name><surname>Poltorak</surname><given-names>A.</given-names></name></person-group><article-title>Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis</article-title><source>Cell Death Differ.</source><volume>26</volume><year>2019</year><fpage>332</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">29786074</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Zorin</surname><given-names>V.</given-names></name><name><surname>Zorina</surname><given-names>A.</given-names></name><name><surname>Smetanina</surname><given-names>N.</given-names></name><name><surname>Kopnin</surname><given-names>P.</given-names></name><name><surname>Ozerov</surname><given-names>I.V.</given-names></name><name><surname>Leonov</surname><given-names>S.</given-names></name><name><surname>Isaev</surname><given-names>A.</given-names></name><name><surname>Klokov</surname><given-names>D.</given-names></name><name><surname>Osipov</surname><given-names>A.N.</given-names></name></person-group><article-title>Diffuse colonies of human skin fibroblasts in relation to cellular senescence and proliferation</article-title><source>Aging (Albany. NY)</source><volume>9</volume><year>2017</year><fpage>1404</fpage><lpage>1413</lpage><pub-id pub-id-type="pmid">28522793</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Torgovnick</surname><given-names>A.</given-names></name><name><surname>Schumacher</surname><given-names>B.</given-names></name></person-group><article-title>DNA repair mechanisms in cancer development and therapy</article-title><source>Front. Genet.</source><volume>6</volume><year>2015</year></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Kholodenko</surname><given-names>R.</given-names></name><name><surname>Grekhova</surname><given-names>A.</given-names></name><name><surname>Suntsova</surname><given-names>M.</given-names></name><name><surname>Pustovalova</surname><given-names>M.</given-names></name><name><surname>Vorobyeva</surname><given-names>N.</given-names></name><name><surname>Kholodenko</surname><given-names>I.</given-names></name><name><surname>Malakhova</surname><given-names>G.</given-names></name><name><surname>Garazha</surname><given-names>A.</given-names></name><name><surname>Nedoluzhko</surname><given-names>A.</given-names></name><name><surname>Vasilov</surname><given-names>R.</given-names></name><name><surname>Poddubskaya</surname><given-names>E.</given-names></name><name><surname>Kovalchuk</surname><given-names>O.</given-names></name><name><surname>Adamyan</surname><given-names>L.</given-names></name><name><surname>Prassolov</surname><given-names>V.</given-names></name><name><surname>Allina</surname><given-names>D.</given-names></name><name><surname>Kuzmin</surname><given-names>D.</given-names></name><name><surname>Ignatev</surname><given-names>K.</given-names></name><name><surname>Osipov</surname><given-names>A.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name></person-group><article-title>Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation</article-title><source>Oncotarget</source><volume>9</volume><year>2018</year><fpage>5111</fpage><lpage>5124</lpage><pub-id pub-id-type="pmid">29435166</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Kalasauskas</surname><given-names>D.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Sprang</surname><given-names>B.</given-names></name><name><surname>Elmasri</surname><given-names>A.</given-names></name><name><surname>Viehweg</surname><given-names>S.</given-names></name><name><surname>Salinas</surname><given-names>G.</given-names></name><name><surname>Opitz</surname><given-names>L.</given-names></name><name><surname>Rave-Fraenk</surname><given-names>M.</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>W.</given-names></name><name><surname>Kantelhardt</surname><given-names>S.R.</given-names></name><name><surname>Giese</surname><given-names>A.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name><name><surname>Kim</surname><given-names>E.L.</given-names></name></person-group><article-title>Diversity of clinically relevant outcomes resulting from hypofractionated radiation in human glioma stem cells mirrors distinct patterns of transcriptomic changes</article-title><source>Cancers</source><volume>12</volume><year>2020</year></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Kiwerska</surname><given-names>K.</given-names></name><name><surname>Szyfter</surname><given-names>K.</given-names></name></person-group><article-title>DNA repair in cancer initiation, progression, and therapy&#x02014;a double-edged sword</article-title><source>J.&#x000a0;Appl. Genet.</source><volume>60</volume><year>2019</year><fpage>329</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">31468363</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.L.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Kantelhardt</surname><given-names>S.R.</given-names></name><name><surname>Kalasauskas</surname><given-names>D.</given-names></name><name><surname>Sprang</surname><given-names>B.</given-names></name><name><surname>Fauss</surname><given-names>J.</given-names></name><name><surname>Ringel</surname><given-names>F.</given-names></name><name><surname>Garazha</surname><given-names>A.</given-names></name><name><surname>Albert</surname><given-names>E.</given-names></name><name><surname>Gaifullin</surname><given-names>N.</given-names></name><name><surname>Hartmann</surname><given-names>C.</given-names></name><name><surname>Naumann</surname><given-names>N.</given-names></name><name><surname>Bikar</surname><given-names>S.-E.E.</given-names></name><name><surname>Giese</surname><given-names>A.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name></person-group><article-title>Intratumoral heterogeneity and longitudinal changes in gene expression predict differential drug sensitivity in newly diagnosed and recurrent glioblastoma</article-title><source>Cancers</source><volume>12</volume><year>2020</year><fpage>520</fpage></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Noda</surname><given-names>A.</given-names></name></person-group><article-title>Radiation-induced unrepairable DSBs: their role in the late effects of radiation and possible applications to biodosimetry</article-title><source>J.&#x000a0;Radiat. Res.</source><volume>59</volume><year>2018</year><fpage>114</fpage><lpage>120</lpage></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Nogueira</surname><given-names>G.A.S.</given-names></name><name><surname>Costa</surname><given-names>E.F.D.</given-names></name><name><surname>Lopes-Aguiar</surname><given-names>L.</given-names></name><name><surname>Lima</surname><given-names>T.R.P.</given-names></name><name><surname>Visacri</surname><given-names>M.B.</given-names></name><name><surname>Pincinato</surname><given-names>E.C.</given-names></name><name><surname>Louren&#x000e7;o</surname><given-names>G.J.</given-names></name><name><surname>Calonga</surname><given-names>L.</given-names></name><name><surname>Mariano</surname><given-names>F.V.</given-names></name><name><surname>de A.M. Altemani</surname><given-names>A.M.</given-names></name><name><surname>Altemani</surname><given-names>J.M.C.</given-names></name><name><surname>Moriel</surname><given-names>P.</given-names></name><name><surname>Chone</surname><given-names>C.T.</given-names></name><name><surname>Ramos</surname><given-names>C.D.</given-names></name><name><surname>Lima</surname><given-names>C.S.P.</given-names></name></person-group><article-title>Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients</article-title><source>Oncotarget</source><volume>9</volume><year>2018</year><fpage>29538</fpage><lpage>29547</lpage><pub-id pub-id-type="pmid">30038702</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>L.P.</given-names></name><name><surname>Hamilton</surname><given-names>T.C.</given-names></name><name><surname>Schilder</surname><given-names>R.J.</given-names></name></person-group><article-title>Platinum resistance: the role of DNA repair pathways</article-title><source>Clin. Canc. Res.</source><volume>14</volume><year>2008</year><fpage>1291</fpage><lpage>1295</lpage></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Paulsson</surname><given-names>J.O.</given-names></name><name><surname>Backman</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Stenman</surname><given-names>A.</given-names></name><name><surname>Crona</surname><given-names>J.</given-names></name><name><surname>Thutkawkorapin</surname><given-names>J.</given-names></name><name><surname>Ghaderi</surname><given-names>M.</given-names></name><name><surname>Tham</surname><given-names>E.</given-names></name><name><surname>St&#x000e5;lberg</surname><given-names>P.</given-names></name><name><surname>Zedenius</surname><given-names>J.</given-names></name><name><surname>Juhlin</surname><given-names>C.C.</given-names></name></person-group><article-title>Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation</article-title><source>J.&#x000a0;Pathol.</source><volume>250</volume><year>2020</year><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">31621921</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Wojtas</surname><given-names>B.</given-names></name><name><surname>Pfeifer</surname><given-names>A.</given-names></name><name><surname>Oczko-Wojciechowska</surname><given-names>M.</given-names></name><name><surname>Krajewska</surname><given-names>J.</given-names></name><name><surname>Czarniecka</surname><given-names>A.</given-names></name><name><surname>Kukulska</surname><given-names>A.</given-names></name><name><surname>Eszlinger</surname><given-names>M.</given-names></name><name><surname>Musholt</surname><given-names>T.</given-names></name><name><surname>Stokowy</surname><given-names>T.</given-names></name><name><surname>Swierniak</surname><given-names>M.</given-names></name><name><surname>Stobiecka</surname><given-names>E.</given-names></name><name><surname>Chmielik</surname><given-names>E.</given-names></name><name><surname>Rusinek</surname><given-names>D.</given-names></name><name><surname>Tyszkiewicz</surname><given-names>T.</given-names></name><name><surname>Halczok</surname><given-names>M.</given-names></name><name><surname>Hauptmann</surname><given-names>S.</given-names></name><name><surname>Lange</surname><given-names>D.</given-names></name><name><surname>Jarzab</surname><given-names>M.</given-names></name><name><surname>Paschke</surname><given-names>R.</given-names></name><name><surname>Jarzab</surname><given-names>B.</given-names></name></person-group><article-title>Gene expression (mRNA) markers for differentiating between malignant and benign follicular thyroid tumours</article-title><source>Int. J. Mol. Sci.</source><volume>18</volume><year>2017</year><fpage>1184</fpage></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Fang</surname><given-names>Q.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Ge</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>P.</given-names></name></person-group><article-title>Integrated bioinformatics analysis of master regulators in anaplastic thyroid carcinoma</article-title><source>BioMed Res. Int.</source><volume>2019</volume><year>2019</year></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Prete</surname><given-names>A.</given-names></name><name><surname>Borges de Souza</surname><given-names>P.</given-names></name><name><surname>Censi</surname><given-names>S.</given-names></name><name><surname>Muzza</surname><given-names>M.</given-names></name><name><surname>Nucci</surname><given-names>N.</given-names></name><name><surname>Sponziello</surname><given-names>M.</given-names></name></person-group><article-title>Update on fundamental mechanisms of thyroid cancer</article-title><source>Front. Endocrinol.</source><volume>11</volume><year>2020</year><fpage>102</fpage></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Buzdin</surname><given-names>A.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Garazha</surname><given-names>A.</given-names></name><name><surname>Glusker</surname><given-names>A.</given-names></name><name><surname>Aleshin</surname><given-names>A.</given-names></name><name><surname>Poddubskaya</surname><given-names>E.</given-names></name><name><surname>Sekacheva</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Gaifullin</surname><given-names>N.</given-names></name><name><surname>Giese</surname><given-names>A.</given-names></name><name><surname>Seryakov</surname><given-names>A.</given-names></name><name><surname>Rumiantsev</surname><given-names>P.</given-names></name><name><surname>Moshkovskii</surname><given-names>S.</given-names></name><name><surname>Moiseev</surname><given-names>A.</given-names></name></person-group><article-title>RNA sequencing for research and diagnostics in clinical oncology</article-title><source>Semin. Canc. Biol.</source><volume>60</volume><year>2019</year><fpage>311</fpage><lpage>323</lpage></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>R.L.</given-names></name><name><surname>Heath</surname><given-names>A.P.</given-names></name><name><surname>Ferretti</surname><given-names>V.</given-names></name><name><surname>Varmus</surname><given-names>H.E.</given-names></name><name><surname>Lowy</surname><given-names>D.R.</given-names></name><name><surname>Kibbe</surname><given-names>W.A.</given-names></name><name><surname>Staudt</surname><given-names>L.M.</given-names></name></person-group><article-title>Toward a shared vision for cancer genomic data</article-title><source>N.&#x000a0;Engl. J. Med.</source><volume>375</volume><year>2016</year><fpage>1109</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">27653561</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Vierlinger</surname><given-names>K.</given-names></name><name><surname>Mansfeld</surname><given-names>M.H.</given-names></name><name><surname>Koperek</surname><given-names>O.</given-names></name><name><surname>N&#x000f6;hammer</surname><given-names>C.</given-names></name><name><surname>Kaserer</surname><given-names>K.</given-names></name><name><surname>Leisch</surname><given-names>F.</given-names></name></person-group><article-title>Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation</article-title><source>BMC Med. Genom.</source><volume>4</volume><year>2011</year><fpage>30</fpage></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.A.</given-names></name></person-group><article-title>Cooperative instruction of signaling and metabolic pathways on the epigenetic landscape</article-title><source>Mol. Cell.</source><volume>41</volume><year>2018</year><fpage>264</fpage><lpage>270</lpage></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Simms</surname><given-names>A.</given-names></name><name><surname>Jacob</surname><given-names>R.P.</given-names></name><name><surname>Cohen</surname><given-names>C.</given-names></name><name><surname>Siddiqui</surname><given-names>M.T.</given-names></name></person-group><article-title>TROP-2 expression in papillary thyroid carcinoma: potential Diagnostic Utility</article-title><source>Diagn. Cytopathol.</source><volume>44</volume><year>2016</year><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">26481593</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>de Morais</surname><given-names>R.M.</given-names></name><name><surname>Sobrinho</surname><given-names>A.B.</given-names></name><name><surname>de S. Silva</surname><given-names>C.M.</given-names></name><name><surname>de Oliveira</surname><given-names>J.R.</given-names></name><name><surname>da Silva</surname><given-names>I.C.R.</given-names></name><name><surname>de T. N&#x000f3;brega</surname><given-names>O.</given-names></name></person-group><article-title>The role of the NIS (SLC5A5) gene in papillary thyroid cancer: a systematic review</article-title><source>Internet J. Endocrinol.</source><volume>2018</volume><year>2018</year></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Morari</surname><given-names>E.C.</given-names></name><name><surname>Marcello</surname><given-names>M.A.</given-names></name><name><surname>Guilhen</surname><given-names>A.C.T.</given-names></name><name><surname>Cunha</surname><given-names>L.L.</given-names></name><name><surname>Latuff</surname><given-names>P.</given-names></name><name><surname>Soares</surname><given-names>F.A.</given-names></name><name><surname>Vassallo</surname><given-names>J.</given-names></name><name><surname>Ward</surname><given-names>L.S.</given-names></name></person-group><article-title>Use of sodium iodide symporter expression in differentiated thyroid carcinomas</article-title><source>Clin. Endocrinol.</source><volume>75</volume><year>2011</year><fpage>247</fpage><lpage>254</lpage></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Tavares</surname><given-names>C.</given-names></name><name><surname>Coelho</surname><given-names>M.J.</given-names></name><name><surname>Eloy</surname><given-names>C.</given-names></name><name><surname>Melo</surname><given-names>M.</given-names></name><name><surname>da Rocha</surname><given-names>A.G.</given-names></name><name><surname>Pestana</surname><given-names>A.</given-names></name><name><surname>Batista</surname><given-names>R.</given-names></name><name><surname>Ferreira</surname><given-names>L.B.</given-names></name><name><surname>Rios</surname><given-names>E.</given-names></name><name><surname>Selmi-Ruby</surname><given-names>S.</given-names></name><name><surname>Cavadas</surname><given-names>B.</given-names></name><name><surname>Pereira</surname><given-names>L.</given-names></name><name><surname>Sim&#x000f5;es</surname><given-names>M.S.</given-names></name><name><surname>Soares</surname><given-names>P.</given-names></name></person-group><article-title>NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features</article-title><source>Endocr. Connect.</source><volume>7</volume><year>2018</year><fpage>78</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">29298843</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Ameziane-El-Hassani</surname><given-names>R.</given-names></name><name><surname>Schlumberger</surname><given-names>M.</given-names></name><name><surname>Dupuy</surname><given-names>C.</given-names></name></person-group><article-title>NADPH oxidases: new actors in thyroid cancer?</article-title><source>Nat. Rev. Endocrinol.</source><volume>12</volume><year>2016</year><fpage>485</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">27174022</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Czarniecka</surname><given-names>A.</given-names></name><name><surname>Oczko-Wojciechowska</surname><given-names>M.</given-names></name><name><surname>Barczy&#x00144;ski</surname><given-names>M.</given-names></name></person-group><article-title>BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence</article-title><source>Gland Surg.</source><volume>5</volume><year>2016</year><fpage>495</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">27867864</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Borisov</surname><given-names>N.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Garazha</surname><given-names>A.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name></person-group><article-title>Quantitation of molecular pathway activation using RNA sequencing data</article-title><source>Methods Mol. Biol.</source><volume>2063</volume><year>2020</year><fpage>189</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">31667772</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Buzdin</surname><given-names>A.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Garazha</surname><given-names>A.</given-names></name><name><surname>Sekacheva</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Zhukov</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Kar</surname><given-names>S.</given-names></name><name><surname>Hartmann</surname><given-names>C.</given-names></name><name><surname>Samii</surname><given-names>A.</given-names></name><name><surname>Giese</surname><given-names>A.</given-names></name><name><surname>Borisov</surname><given-names>N.</given-names></name></person-group><article-title>Molecular pathway activation - new type of biomarkers for tumor morphology and personalized selection of target drugs</article-title><source>Semin. Canc. Biol.</source><volume>53</volume><year>2018</year><fpage>110</fpage><lpage>124</lpage></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Croft</surname><given-names>D.</given-names></name><name><surname>Mundo</surname><given-names>A.F.</given-names></name><name><surname>Haw</surname><given-names>R.</given-names></name><name><surname>Milacic</surname><given-names>M.</given-names></name><name><surname>Weiser</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Caudy</surname><given-names>M.</given-names></name><name><surname>Garapati</surname><given-names>P.</given-names></name><name><surname>Gillespie</surname><given-names>M.</given-names></name><name><surname>Kamdar</surname><given-names>M.R.</given-names></name><name><surname>Jassal</surname><given-names>B.</given-names></name><name><surname>Jupe</surname><given-names>S.</given-names></name><name><surname>Matthews</surname><given-names>L.</given-names></name><name><surname>May</surname><given-names>B.</given-names></name><name><surname>Palatnik</surname><given-names>S.</given-names></name><name><surname>Rothfels</surname><given-names>K.</given-names></name><name><surname>Shamovsky</surname><given-names>V.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Williams</surname><given-names>M.</given-names></name><name><surname>Birney</surname><given-names>E.</given-names></name><name><surname>Hermjakob</surname><given-names>H.</given-names></name><name><surname>Stein</surname><given-names>L.</given-names></name><name><surname>D&#x02019;Eustachio</surname><given-names>P.</given-names></name></person-group><article-title>The Reactome pathway knowledgebase</article-title><source>Nucleic Acids Res.</source><volume>42</volume><year>2014</year><fpage>D472</fpage><lpage>D477</lpage><pub-id pub-id-type="pmid">24243840</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>C.F.</given-names></name><name><surname>Anthony</surname><given-names>K.</given-names></name><name><surname>Krupa</surname><given-names>S.</given-names></name><name><surname>Buchoff</surname><given-names>J.</given-names></name><name><surname>Day</surname><given-names>M.</given-names></name><name><surname>Hannay</surname><given-names>T.</given-names></name><name><surname>Buetow</surname><given-names>K.H.</given-names></name></person-group><article-title>PID: the pathway interaction database</article-title><source>Nucleic Acids Res.</source><volume>37</volume><year>2009</year><fpage>D674</fpage><lpage>D679</lpage><pub-id pub-id-type="pmid">18832364</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M.</given-names></name><name><surname>Goto</surname><given-names>S.</given-names></name></person-group><article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Res.</source><volume>28</volume><year>2000</year><fpage>27</fpage><lpage>30</lpage><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/10592173" id="intref0030">http://www.ncbi.nlm.nih.gov/pubmed/10592173</ext-link><pub-id pub-id-type="pmid">10592173</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>D.</given-names></name></person-group><article-title>BioCarta, Biotech Softw</article-title><source>Internet Rep.</source><volume>2</volume><year>2001</year><fpage>117</fpage><lpage>120</lpage></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="other" id="sref44"><article-title>QIAGEN - Pathway-Central</article-title><comment>(n.d)</comment><ext-link ext-link-type="uri" xlink:href="https://www.qiagen.com/us/shop/genes-and-pathways/pathway-central/" id="intref0035">https://www.qiagen.com/us/shop/genes-and-pathways/pathway-central/</ext-link></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Suntsova</surname><given-names>M.</given-names></name><name><surname>Gaifullin</surname><given-names>N.</given-names></name><name><surname>Allina</surname><given-names>D.</given-names></name><name><surname>Reshetun</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Mendeleeva</surname><given-names>L.</given-names></name><name><surname>Surin</surname><given-names>V.</given-names></name><name><surname>Sergeeva</surname><given-names>A.</given-names></name><name><surname>Spirin</surname><given-names>P.</given-names></name><name><surname>Prassolov</surname><given-names>V.</given-names></name><name><surname>Morgan</surname><given-names>A.</given-names></name><name><surname>Garazha</surname><given-names>A.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name></person-group><article-title>Atlas of RNA sequencing profiles for normal human tissues</article-title><source>Sci. Data.</source><volume>6</volume><year>2019</year><fpage>36</fpage><pub-id pub-id-type="pmid">31015567</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>N.</given-names></name><name><surname>Walker</surname><given-names>G.C.</given-names></name></person-group><article-title>Mechanisms of DNA damage, repair, and mutagenesis</article-title><source>Environ. Mol. Mutagen.</source><volume>58</volume><year>2017</year><fpage>235</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">28485537</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Moldovan</surname><given-names>G.L.</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>A.D.</given-names></name></person-group><article-title>How the fanconi anemia pathway guards the genome</article-title><source>Annu. Rev. Genet.</source><volume>43</volume><year>2009</year><fpage>223</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">19686080</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>V.</given-names></name><name><surname>Povirk</surname><given-names>L.</given-names></name></person-group><article-title>Involvement of p53 in the repair of DNA double strand breaks: multifaceted roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ)</article-title><source>Subcell. Biochem.</source><volume>85</volume><year>2014</year><fpage>321</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">25201202</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>A.B.</given-names></name><name><surname>Schumacher</surname><given-names>B.</given-names></name></person-group><article-title>p53 in the DNA-damage-repair process</article-title><source>Cold Spring Harb. Perspect. Med.</source><volume>6</volume><year>2016</year></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Reinhardt</surname><given-names>H.C.</given-names></name><name><surname>Schumacher</surname><given-names>B.</given-names></name></person-group><article-title>The p53 network: cellular and systemic DNA damage responses in aging and cancer</article-title><source>Trends Genet.</source><volume>28</volume><year>2012</year><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">22265392</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>L.Y.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name></person-group><article-title>The role of BRCA1 in DNA damage response</article-title><source>Protein Cell</source><volume>1</volume><year>2010</year><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">21203981</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>R.</given-names></name><name><surname>Chun</surname><given-names>J.</given-names></name><name><surname>Powell</surname><given-names>S.N.</given-names></name></person-group><article-title>BRCA1 and BRCA2: different roles in a common pathway of genome protection</article-title><source>Nat. Rev. Canc.</source><volume>12</volume><year>2012</year><fpage>68</fpage><lpage>78</lpage></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name></person-group><article-title>Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer</article-title><source>Canc. Gene Ther.</source><volume>20</volume><year>2013</year><fpage>260</fpage><lpage>266</lpage></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name></person-group><article-title>Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress</article-title><source>PloS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e111911</object-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G.</given-names></name><name><surname>Mlecnik</surname><given-names>B.</given-names></name><name><surname>Hackl</surname><given-names>H.</given-names></name><name><surname>Charoentong</surname><given-names>P.</given-names></name><name><surname>Tosolini</surname><given-names>M.</given-names></name><name><surname>Kirilovsky</surname><given-names>A.</given-names></name><name><surname>Fridman</surname><given-names>W.-H.</given-names></name><name><surname>Pag&#x000e8;s</surname><given-names>F.</given-names></name><name><surname>Trajanoski</surname><given-names>Z.</given-names></name><name><surname>Galon</surname><given-names>J.</given-names></name></person-group><article-title>ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks</article-title><source>Bioinformatics</source><volume>25</volume><year>2009</year><fpage>1091</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">19237447</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="book" id="sref56"><person-group person-group-type="author"><name><surname>Bravo</surname><given-names>R.</given-names></name><name><surname>Parra</surname><given-names>V.</given-names></name><name><surname>Gatica</surname><given-names>D.</given-names></name><name><surname>Rodriguez</surname><given-names>A.E.</given-names></name><name><surname>Torrealba</surname><given-names>N.</given-names></name><name><surname>Paredes</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>Z.V.</given-names></name><name><surname>Zorzano</surname><given-names>A.</given-names></name><name><surname>Hill</surname><given-names>J.A.</given-names></name><name><surname>Jaimovich</surname><given-names>E.</given-names></name><name><surname>Quest</surname><given-names>A.F.G.</given-names></name><name><surname>Lavandero</surname><given-names>S.</given-names></name></person-group><chapter-title>Endoplasmic reticulum and the unfolded protein response. Dynamics and metabolic integration</chapter-title><source>Int. Rev. Cell Mol. Biol.</source><year>2013</year><publisher-name>Elsevier Inc.</publisher-name><fpage>215</fpage><lpage>290</lpage></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.Y.</given-names></name><name><surname>Kaufman</surname><given-names>R.J.</given-names></name></person-group><article-title>The unfolded protein response</article-title><source>J.&#x000a0;Cell Sci.</source><volume>116</volume><year>2003</year><fpage>1861</fpage><lpage>1862</lpage><pub-id pub-id-type="pmid">12692187</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>T.M.</given-names></name><name><surname>Ritchie</surname><given-names>J.E.</given-names></name><name><surname>Kanthou</surname><given-names>C.</given-names></name><name><surname>Staves</surname><given-names>J.J.</given-names></name><name><surname>Narramore</surname><given-names>R.</given-names></name><name><surname>Wyld</surname><given-names>L.</given-names></name></person-group><article-title>Targeting the endoplasmic reticulum mediates radiation sensitivity in colorectal cancer</article-title><source>Exp. Mol. Pathol.</source><volume>98</volume><year>2015</year><fpage>532</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">25825019</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Barski</surname><given-names>O.A.</given-names></name><name><surname>Tipparaju</surname><given-names>S.M.</given-names></name><name><surname>Bhatnagar</surname><given-names>A.</given-names></name></person-group><article-title>The aldo-keto reductase superfamily and its role in drug metabolism and detoxification</article-title><source>Drug Metab. Rev.</source><volume>40</volume><year>2008</year><fpage>553</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">18949601</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S.Q.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>X.S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Xiong</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Teng</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name></person-group><article-title>Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation</article-title><source>Oncotarget</source><volume>7</volume><year>2016</year><fpage>48050</fpage><lpage>48058</lpage><pub-id pub-id-type="pmid">27385003</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.-S.</given-names></name><name><surname>Wook Chang</surname><given-names>J.</given-names></name><name><surname>Kuk Park</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>S.-G.</given-names></name></person-group><article-title>Increased aldehyde reductase expression mediates acquired radioresistance of laryngeal cancer cells via modulating p53 View supplementary material</article-title><source>Canc. Biol. Ther.</source><volume>13</volume><year>2012</year><fpage>638</fpage><lpage>646</lpage></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="book" id="sref62"><person-group person-group-type="author"><name><surname>Safran</surname><given-names>M.</given-names></name><name><surname>Dalah</surname><given-names>I.</given-names></name><name><surname>Alexander</surname><given-names>J.</given-names></name><name><surname>Rosen</surname><given-names>N.</given-names></name><name><surname>Stein</surname><given-names>T.I.</given-names></name><name><surname>Shmoish</surname><given-names>M.</given-names></name><name><surname>Nativ</surname><given-names>N.</given-names></name><name><surname>Bahir</surname><given-names>I.</given-names></name><name><surname>Doniger</surname><given-names>T.</given-names></name><name><surname>Krug</surname><given-names>H.</given-names></name><name><surname>Sirota-Madi</surname><given-names>A.</given-names></name><name><surname>Olender</surname><given-names>T.</given-names></name><name><surname>Golan</surname><given-names>Y.</given-names></name><name><surname>Stelzer</surname><given-names>G.</given-names></name><name><surname>Harel</surname><given-names>A.</given-names></name><name><surname>Lancet</surname><given-names>D.</given-names></name></person-group><chapter-title>GeneCards Version 3: the Human Gene Integrator, Database. 2010</chapter-title><year>2010</year><object-id pub-id-type="publisher-id">baq020</object-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Palacios</surname><given-names>D.A.</given-names></name><name><surname>Miyake</surname><given-names>M.</given-names></name><name><surname>Rosser</surname><given-names>C.J.</given-names></name></person-group><article-title>Radiosensitization in prostate cancer: mechanisms and targets</article-title><source>BMC Urol.</source><volume>13</volume><year>2013</year><fpage>4</fpage><pub-id pub-id-type="pmid">23351141</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.T.</given-names></name><name><surname>Lim</surname><given-names>D.S.</given-names></name><name><surname>Canman</surname><given-names>C.E.</given-names></name><name><surname>Kastan</surname><given-names>M.B.</given-names></name></person-group><article-title>Substrate specificities and identification of putative substrates of ATM kinase family members</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>274</volume><year>1999</year><fpage>37538</fpage><lpage>37543</lpage><pub-id pub-id-type="pmid">10608806</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>J.A.</given-names></name><name><surname>Keegan</surname><given-names>K.S.</given-names></name><name><surname>Herendeen</surname><given-names>D.R.</given-names></name><name><surname>Bentley</surname><given-names>N.J.</given-names></name><name><surname>Carr</surname><given-names>A.M.</given-names></name><name><surname>Hoekstra</surname><given-names>M.F.</given-names></name><name><surname>Concannon</surname><given-names>P.</given-names></name></person-group><article-title>Protein kinase mutants of human ATR increase sensitivity to UV and ionizing radiation and abrogate cell cycle checkpoint control</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>95</volume><year>1998</year><fpage>7445</fpage><lpage>7450</lpage><pub-id pub-id-type="pmid">9636169</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>R.T.</given-names></name></person-group><article-title>Checkpoint signaling: epigenetic events sound the DNA strand-breaks alarm to the ATM protein kinase</article-title><source>Bioessays</source><volume>25</volume><year>2003</year><fpage>627</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">12815717</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Bakkenist</surname><given-names>C.J.</given-names></name><name><surname>Kastan</surname><given-names>M.B.</given-names></name></person-group><article-title>DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation</article-title><source>Nature</source><volume>421</volume><year>2003</year><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">12556884</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Lien</surname><given-names>E.C.</given-names></name><name><surname>Dibble</surname><given-names>C.C.</given-names></name><name><surname>Toker</surname><given-names>A.</given-names></name></person-group><article-title>PI3K signaling in cancer: beyond AKT</article-title><source>Curr. Opin. Cell Biol.</source><volume>45</volume><year>2017</year><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">28343126</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Greer</surname><given-names>P.M.</given-names></name><name><surname>Cao</surname><given-names>P.T.</given-names></name><name><surname>Kolb</surname><given-names>R.H.</given-names></name><name><surname>Cowan</surname><given-names>K.H.</given-names></name></person-group><article-title>RAC1 GTPase plays an important role in &#x003b3;-irradiation induced G 2/M checkpoint activation</article-title><source>Breast Cancer Res.</source><volume>14</volume><year>2012</year><fpage>R60</fpage><pub-id pub-id-type="pmid">22494620</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="book" id="sref70"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Hein</surname><given-names>A.</given-names></name><name><surname>Etekpo</surname><given-names>A.</given-names></name><name><surname>Burchett</surname><given-names>K.</given-names></name><name><surname>Oncotarget</surname><given-names>C.L.</given-names></name><name><surname>undefined</surname></name></person-group><chapter-title>Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to &#x003b3;-irradiation, Ncbi.Nlm.Nih.GovPaperpile</chapter-title><year>2014</year><comment>(n.d.)</comment><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4279370/" id="intref0040">https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4279370/</ext-link></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Del Mar Maldonado</surname><given-names>M.</given-names></name><name><surname>Dharmawardhane</surname><given-names>S.</given-names></name></person-group><article-title>Targeting rac and Cdc42 GT pases in cancer</article-title><source>Canc. Res.</source><volume>78</volume><year>2018</year><fpage>3101</fpage><lpage>3111</lpage></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.K.</given-names></name><name><surname>Guo</surname><given-names>Z.P.</given-names></name><name><surname>Guan</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.D.</given-names></name><name><surname>Xie</surname><given-names>D.F.</given-names></name><name><surname>Jiang</surname><given-names>Y.G.</given-names></name><name><surname>Ma</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>P.K.</given-names></name></person-group><article-title>RBX1 prompts degradation of EXO1 to limit the homologous recombination pathway of DNA double-strand break repair in G1 phase</article-title><source>Cell Death Differ.</source><volume>27</volume><year>2020</year><fpage>1383</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">31562368</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>L.</given-names></name><name><surname>Bickel</surname><given-names>J.S.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Morgan</surname><given-names>M.A.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Chan</surname><given-names>R.C.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name></person-group><article-title>RBX1 (RING box protein 1) E3 ubiquitin ligase is required for genomic integrity by modulating DNA replication licensing proteins</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>286</volume><year>2011</year><fpage>3379</fpage><lpage>3386</lpage><pub-id pub-id-type="pmid">21115485</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>S.M.</given-names></name><name><surname>Sharp</surname><given-names>M.G.F.</given-names></name><name><surname>Walker</surname><given-names>R.A.</given-names></name><name><surname>Brammar</surname><given-names>W.J.</given-names></name><name><surname>Varley</surname><given-names>J.M.</given-names></name></person-group><article-title>Differential expression of translation-associated genes in benign and malignant human breast tumours</article-title><source>Br. J. Canc.</source><volume>65</volume><year>1992</year><fpage>65</fpage><lpage>71</lpage></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="book" id="sref75"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>J.M.</given-names></name><name><surname>Manine</surname><given-names>K.-I.</given-names></name><name><surname>Yow</surname><given-names>H.</given-names></name><name><surname>Rivers</surname><given-names>E.N.</given-names></name><name><surname>Ravikumar</surname><given-names>T.S.</given-names></name><name><surname>Steele</surname><given-names>G.D.</given-names></name><name><surname>Chen</surname><given-names>L.B.</given-names></name></person-group><chapter-title>Ubiquitin-Ribosomal Protein S27a Gene Overexpressed in Human Colorectal Carcinoma Is an Early Growth Response Gene1</chapter-title><year>1916</year><ext-link ext-link-type="uri" xlink:href="https://cancerres.aacrjournals.org/content/53/8/1916.short" id="intref0045">https://cancerres.aacrjournals.org/content/53/8/1916.short</ext-link></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Xing</surname><given-names>H.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name><name><surname>Tang</surname><given-names>K.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Rao</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>446</volume><year>2014</year><fpage>1204</fpage><lpage>1210</lpage><pub-id pub-id-type="pmid">24680683</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Geng</surname><given-names>Y.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Meng</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name></person-group><article-title>Downregulation of ubiquitin inhibits the proliferation and radioresistance of non-small cell lung cancer cells in vitro and in vivo</article-title><source>Sci. Rep.</source><volume>5</volume><year>2015</year><fpage>1</fpage><lpage>12</lpage></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Scanlon</surname><given-names>S.E.</given-names></name><name><surname>Glazer</surname><given-names>P.M.</given-names></name></person-group><article-title>Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment</article-title><source>DNA Repair</source><volume>32</volume><year>2015</year><fpage>180</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">25956861</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Thierry-Mieg</surname><given-names>D.</given-names></name><name><surname>Thierry-Mieg</surname><given-names>J.</given-names></name></person-group><article-title>AceView: a comprehensive cDNA-supported gene and transcripts annotation</article-title><source>Genome Biol.</source><volume>7</volume><issue>Suppl 1</issue><year>2006</year><fpage>S12</fpage><comment>1-14</comment><pub-id pub-id-type="pmid">16925834</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="book" id="sref80"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>S.</given-names></name><name><surname>others</surname></name></person-group><chapter-title>FastQC: a Quality Control Tool for High Throughput Sequence Data</chapter-title><year>2010</year></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Zolotovskaia</surname><given-names>M.A.</given-names></name><name><surname>Tkachev</surname><given-names>V.S.</given-names></name><name><surname>Seryakov</surname><given-names>A.P.</given-names></name><name><surname>Kuzmin</surname><given-names>D.V.</given-names></name><name><surname>Kamashev</surname><given-names>D.E.</given-names></name><name><surname>Sorokin</surname><given-names>M.I.</given-names></name><name><surname>Roumiantsev</surname><given-names>S.A.</given-names></name><name><surname>Buzdin</surname><given-names>A.A.</given-names></name></person-group><article-title>Mutation enrichment and transcriptomic activation signatures of 419 molecular pathways in cancer</article-title><source>Cancers</source><volume>12</volume><year>2020</year></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Borisov</surname><given-names>N.</given-names></name><name><surname>Suntsova</surname><given-names>M.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Garazha</surname><given-names>A.</given-names></name><name><surname>Kovalchuk</surname><given-names>O.</given-names></name><name><surname>Aliper</surname><given-names>A.</given-names></name><name><surname>Ilnitskaya</surname><given-names>E.</given-names></name><name><surname>Lezhnina</surname><given-names>K.</given-names></name><name><surname>Korzinkin</surname><given-names>M.</given-names></name><name><surname>Tkachev</surname><given-names>V.</given-names></name><name><surname>Saenko</surname><given-names>V.</given-names></name><name><surname>Saenko</surname><given-names>Y.</given-names></name><name><surname>Sokov</surname><given-names>D.G.</given-names></name><name><surname>Gaifullin</surname><given-names>N.M.</given-names></name><name><surname>Kashintsev</surname><given-names>K.</given-names></name><name><surname>Shirokorad</surname><given-names>V.</given-names></name><name><surname>Shabalina</surname><given-names>I.</given-names></name><name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><name><surname>Mishra</surname><given-names>B.</given-names></name><name><surname>Cantor</surname><given-names>C.R.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name></person-group><article-title>Data aggregation at the level of molecular pathways improves stability of experimental transcriptomic and proteomic data</article-title><source>Cell Cycle</source><volume>16</volume><year>2017</year><fpage>1810</fpage><lpage>1823</lpage><pub-id pub-id-type="pmid">28825872</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Cherniack</surname><given-names>A.D.</given-names></name><name><surname>Dewal</surname><given-names>N.</given-names></name><name><surname>Moffitt</surname><given-names>R.A.</given-names></name><name><surname>Danilova</surname><given-names>L.</given-names></name><name><surname>Murray</surname><given-names>B.A.</given-names></name><name><surname>Lerario</surname><given-names>A.M.</given-names></name><name><surname>Else</surname><given-names>T.</given-names></name><name><surname>Knijnenburg</surname><given-names>T.A.</given-names></name><name><surname>Ciriello</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Assie</surname><given-names>G.</given-names></name><name><surname>Morozova</surname><given-names>O.</given-names></name><name><surname>Akbani</surname><given-names>R.</given-names></name><name><surname>Shih</surname><given-names>J.</given-names></name><name><surname>Hoadley</surname><given-names>K.A.</given-names></name><name><surname>Choueiri</surname><given-names>T.K.</given-names></name><name><surname>Waldmann</surname><given-names>J.</given-names></name><name><surname>Mete</surname><given-names>O.</given-names></name><name><surname>Robertson</surname><given-names>A.G.</given-names></name><name><surname>Wu</surname><given-names>H.-T.</given-names></name><name><surname>Raphael</surname><given-names>B.J.</given-names></name><name><surname>Shao</surname><given-names>L.</given-names></name><name><surname>Meyerson</surname><given-names>M.</given-names></name><name><surname>Demeure</surname><given-names>M.J.</given-names></name><name><surname>Beuschlein</surname><given-names>F.</given-names></name><name><surname>Gill</surname><given-names>A.J.</given-names></name><name><surname>Sidhu</surname><given-names>S.B.</given-names></name><name><surname>Almeida</surname><given-names>M.Q.</given-names></name><name><surname>V Fragoso</surname><given-names>M.C.B.</given-names></name><name><surname>Cope</surname><given-names>L.M.</given-names></name><name><surname>Kebebew</surname><given-names>E.</given-names></name><name><surname>Habra</surname><given-names>M.A.</given-names></name><name><surname>Whitsett</surname><given-names>T.G.</given-names></name><name><surname>Bussey</surname><given-names>K.J.</given-names></name><name><surname>Rainey</surname><given-names>W.E.</given-names></name><name><surname>Asa</surname><given-names>S.L.</given-names></name><name><surname>Bertherat</surname><given-names>J.</given-names></name><name><surname>Fassnacht</surname><given-names>M.</given-names></name><name><surname>Wheeler</surname><given-names>D.A.</given-names></name><name><surname>Cancer Genome Atlas Research Network</surname><given-names>S.</given-names></name><name><surname>Hammer</surname><given-names>G.D.</given-names></name><name><surname>Giordano</surname><given-names>T.J.</given-names></name><name><surname>Verhaak</surname><given-names>R.G.W.</given-names></name><name><surname>Cherniack</surname><given-names>A.D.</given-names></name><name><surname>Dewal</surname><given-names>N.</given-names></name><name><surname>Moffitt</surname><given-names>R.A.</given-names></name><name><surname>Danilova</surname><given-names>L.</given-names></name><name><surname>Murray</surname><given-names>B.A.</given-names></name><name><surname>Lerario</surname><given-names>A.M.</given-names></name><name><surname>Else</surname><given-names>T.</given-names></name><name><surname>Knijnenburg</surname><given-names>T.A.</given-names></name><name><surname>Ciriello</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Assi&#x000e9;</surname><given-names>G.</given-names></name><name><surname>Morozova</surname><given-names>O.</given-names></name><name><surname>Akbani</surname><given-names>R.</given-names></name><name><surname>Shih</surname><given-names>J.</given-names></name><name><surname>Hoadley</surname><given-names>K.A.</given-names></name><name><surname>Choueiri</surname><given-names>T.K.</given-names></name><name><surname>Waldmann</surname><given-names>J.</given-names></name><name><surname>Mete</surname><given-names>O.</given-names></name><name><surname>Robertson</surname><given-names>A.G.</given-names></name><name><surname>Wu</surname><given-names>H.-T.</given-names></name><name><surname>Raphael</surname><given-names>B.J.</given-names></name><name><surname>Meyerson</surname><given-names>M.</given-names></name><name><surname>Demeure</surname><given-names>M.J.</given-names></name><name><surname>Beuschlein</surname><given-names>F.</given-names></name><name><surname>Gill</surname><given-names>A.J.</given-names></name><name><surname>Sidhu</surname><given-names>S.B.</given-names></name><name><surname>Almeida</surname><given-names>M.</given-names></name><name><surname>Fragoso</surname><given-names>M.C.B.</given-names></name><name><surname>Cope</surname><given-names>L.M.</given-names></name><name><surname>Kebebew</surname><given-names>E.</given-names></name><name><surname>Habra</surname><given-names>M.A.</given-names></name><name><surname>Whitsett</surname><given-names>T.G.</given-names></name><name><surname>Bussey</surname><given-names>K.J.</given-names></name><name><surname>Rainey</surname><given-names>W.E.</given-names></name><name><surname>Asa</surname><given-names>S.L.</given-names></name><name><surname>Bertherat</surname><given-names>J.</given-names></name><name><surname>Fassnacht</surname><given-names>M.</given-names></name><name><surname>Wheeler</surname><given-names>D.A.</given-names></name><name><surname>Benz</surname><given-names>C.</given-names></name><name><surname>Ally</surname><given-names>A.</given-names></name><name><surname>Balasundaram</surname><given-names>M.</given-names></name><name><surname>Bowlby</surname><given-names>R.</given-names></name><name><surname>Brooks</surname><given-names>D.</given-names></name><name><surname>Butterfield</surname><given-names>Y.S.N.</given-names></name><name><surname>Carlsen</surname><given-names>R.</given-names></name><name><surname>Dhalla</surname><given-names>N.</given-names></name><name><surname>Guin</surname><given-names>R.</given-names></name><name><surname>Holt</surname><given-names>R.A.</given-names></name><name><surname>Jones</surname><given-names>S.J.M.</given-names></name><name><surname>Kasaian</surname><given-names>K.</given-names></name><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>H.I.</given-names></name><name><surname>Lim</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Marra</surname><given-names>M.A.</given-names></name><name><surname>Mayo</surname><given-names>M.</given-names></name><name><surname>Moore</surname><given-names>R.A.</given-names></name><name><surname>Mungall</surname><given-names>A.J.</given-names></name><name><surname>Mungall</surname><given-names>K.</given-names></name><name><surname>Sadeghi</surname><given-names>S.</given-names></name><name><surname>Schein</surname><given-names>J.E.</given-names></name><name><surname>Sipahimalani</surname><given-names>P.</given-names></name><name><surname>Tam</surname><given-names>A.</given-names></name><name><surname>Thiessen</surname><given-names>N.</given-names></name><name><surname>Park</surname><given-names>P.J.</given-names></name><name><surname>Kroiss</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Sander</surname><given-names>C.</given-names></name><name><surname>Schultz</surname><given-names>N.</given-names></name><name><surname>Jones</surname><given-names>C.D.</given-names></name><name><surname>Kucherlapati</surname><given-names>R.</given-names></name><name><surname>Mieczkowski</surname><given-names>P.A.</given-names></name><name><surname>Parker</surname><given-names>J.S.</given-names></name><name><surname>Perou</surname><given-names>C.M.</given-names></name><name><surname>Tan</surname><given-names>D.</given-names></name><name><surname>Veluvolu</surname><given-names>U.</given-names></name><name><surname>Wilkerson</surname><given-names>M.D.</given-names></name><name><surname>Hayes</surname><given-names>D.N.</given-names></name><name><surname>Ladanyi</surname><given-names>M.</given-names></name><name><surname>Quinkler</surname><given-names>M.</given-names></name><name><surname>Auman</surname><given-names>J.T.</given-names></name><name><surname>Latronico</surname><given-names>A.C.</given-names></name><name><surname>Mendonca</surname><given-names>B.B.</given-names></name><name><surname>Sibony</surname><given-names>M.</given-names></name><name><surname>Sanborn</surname><given-names>Z.</given-names></name><name><surname>Bellair</surname><given-names>M.</given-names></name><name><surname>Buhay</surname><given-names>C.</given-names></name><name><surname>Covington</surname><given-names>K.</given-names></name><name><surname>Dahdouli</surname><given-names>M.</given-names></name><name><surname>Dinh</surname><given-names>H.</given-names></name><name><surname>Doddapaneni</surname><given-names>H.</given-names></name><name><surname>Downs</surname><given-names>B.</given-names></name><name><surname>Drummond</surname><given-names>J.</given-names></name><name><surname>Gibbs</surname><given-names>R.</given-names></name><name><surname>Hale</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Hawes</surname><given-names>A.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Kakkar</surname><given-names>N.</given-names></name><name><surname>Kalra</surname><given-names>D.</given-names></name><name><surname>Khan</surname><given-names>Z.</given-names></name><name><surname>Kovar</surname><given-names>C.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Lewis</surname><given-names>L.</given-names></name><name><surname>Morgan</surname><given-names>M.</given-names></name><name><surname>Morton</surname><given-names>D.</given-names></name><name><surname>Muzny</surname><given-names>D.</given-names></name><name><surname>Santibanez</surname><given-names>J.</given-names></name><name><surname>Xi</surname><given-names>L.</given-names></name><name><surname>Dousset</surname><given-names>B.</given-names></name><name><surname>Groussin</surname><given-names>L.</given-names></name><name><surname>Lib&#x000e9;</surname><given-names>R.</given-names></name><name><surname>Chin</surname><given-names>L.</given-names></name><name><surname>Reynolds</surname><given-names>S.</given-names></name><name><surname>Shmulevich</surname><given-names>I.</given-names></name><name><surname>Chudamani</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lolla</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Yeh</surname><given-names>J.J.</given-names></name><name><surname>Balu</surname><given-names>S.</given-names></name><name><surname>Bodenheimer</surname><given-names>T.</given-names></name><name><surname>Hoyle</surname><given-names>A.P.</given-names></name><name><surname>Jefferys</surname><given-names>S.R.</given-names></name><name><surname>Meng</surname><given-names>S.</given-names></name><name><surname>Mose</surname><given-names>L.E.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Simons</surname><given-names>J.V.</given-names></name><name><surname>Soloway</surname><given-names>M.G.</given-names></name><name><surname>. Wu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Shaw</surname><given-names>K.R.M.</given-names></name><name><surname>Demchok</surname><given-names>J.A.</given-names></name><name><surname>Felau</surname><given-names>I.</given-names></name><name><surname>Sheth</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>R.Z.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Zenklusen</surname><given-names>J.C.</given-names></name><name><surname>Julia</surname><given-names>J.</given-names></name><name><surname>Zhang</surname></name><name><surname>Davidsen</surname><given-names>T.</given-names></name><name><surname>Crawford</surname><given-names>C.</given-names></name><name><surname>Hutter</surname><given-names>C.M.</given-names></name><name><surname>Sofia</surname><given-names>H.J.</given-names></name><name><surname>Roach</surname><given-names>J.</given-names></name><name><surname>Bshara</surname><given-names>W.</given-names></name><name><surname>Gaudioso</surname><given-names>C.</given-names></name><name><surname>Morrison</surname><given-names>C.</given-names></name><name><surname>Soon</surname><given-names>P.</given-names></name><name><surname>Alonso</surname><given-names>S.</given-names></name><name><surname>Baboud</surname><given-names>J.</given-names></name><name><surname>Pihl</surname><given-names>T.</given-names></name><name><surname>Raman</surname><given-names>R.</given-names></name><name><surname>Sun</surname><given-names>Q.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Naresh</surname><given-names>R.</given-names></name><name><surname>Arachchi</surname><given-names>H.</given-names></name><name><surname>Beroukhim</surname><given-names>R.</given-names></name><name><surname>Carter</surname><given-names>S.L.</given-names></name><name><surname>Cho</surname><given-names>J.</given-names></name><name><surname>Frazer</surname><given-names>S.</given-names></name><name><surname>Gabriel</surname><given-names>S.B.</given-names></name><name><surname>Getz</surname><given-names>G.</given-names></name><name><surname>. Heiman</surname><given-names>D.I.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>. Lawrence</surname><given-names>M.S.</given-names></name><name><surname>Lin</surname><given-names>P.</given-names></name><name><surname>Noble</surname><given-names>M.S.</given-names></name><name><surname>Saksena</surname><given-names>G.</given-names></name><name><surname>Schumacher</surname><given-names>S.E.</given-names></name><name><surname>Sougnez</surname><given-names>C.</given-names></name><name><surname>Voet</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Bowen</surname><given-names>J.</given-names></name><name><surname>Coppens</surname><given-names>S.</given-names></name><name><surname>Gastier-Foster</surname><given-names>J.M.</given-names></name><name><surname>Gerken</surname><given-names>M.</given-names></name><name><surname>Helsel</surname><given-names>C.</given-names></name><name><surname>Leraas</surname><given-names>K.M.</given-names></name><name><surname>Lichtenberg</surname><given-names>T.M.</given-names></name><name><surname>Ramirez</surname><given-names>N.C.</given-names></name><name><surname>Wise</surname><given-names>L.</given-names></name><name><surname>Zmuda</surname><given-names>E.</given-names></name><name><surname>Baylin</surname><given-names>S.</given-names></name><name><surname>Herman</surname><given-names>J.G.</given-names></name><name><surname>LoBello</surname><given-names>J.</given-names></name><name><surname>Watanabe</surname><given-names>A.</given-names></name><name><surname>Haussler</surname><given-names>D.</given-names></name><name><surname>Radenbaugh</surname><given-names>A.</given-names></name><name><surname>Rao</surname><given-names>A.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Bartsch</surname><given-names>D.K.</given-names></name><name><surname>Sbiera</surname><given-names>S.</given-names></name><name><surname>Allolio</surname><given-names>B.</given-names></name><name><surname>Deutschbein</surname><given-names>T.</given-names></name><name><surname>Ronchi</surname><given-names>C.</given-names></name><name><surname>Raymond</surname><given-names>V.M.</given-names></name><name><surname>Vinco</surname><given-names>M.</given-names></name><name><surname>Shao</surname><given-names>L.</given-names></name><name><surname>Amble</surname><given-names>L.</given-names></name><name><surname>Bootwalla</surname><given-names>M.S.</given-names></name><name><surname>Lai</surname><given-names>P.H.</given-names></name><name><surname>Van Den Berg</surname><given-names>D.J.</given-names></name><name><surname>Weisenberger</surname><given-names>D.J.</given-names></name><name><surname>Robinson</surname><given-names>B.</given-names></name><name><surname>Ju</surname><given-names>Z.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Ling</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Mills</surname><given-names>G.B.</given-names></name><name><surname>Sircar</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Yoshihara</surname><given-names>K.</given-names></name><name><surname>Laird</surname><given-names>P.W.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Shinbrot</surname><given-names>E.</given-names></name><name><surname>Reincke</surname><given-names>M.</given-names></name><name><surname>Weinstein</surname><given-names>J.N.</given-names></name><name><surname>Meier</surname><given-names>S.</given-names></name><name><surname>Defreitas</surname><given-names>T.</given-names></name><name><surname>Hammer</surname><given-names>G.D.</given-names></name><name><surname>Giordano</surname><given-names>T.J.</given-names></name><name><surname>Verhaak</surname><given-names>R.G.W.</given-names></name></person-group><article-title>Comprehensive pan-genomic characterization of adrenocortical carcinoma</article-title><source>Canc. Cell</source><volume>29</volume><year>2016</year><fpage>723</fpage><lpage>736</lpage></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Carithers</surname><given-names>L.J.</given-names></name><name><surname>Moore</surname><given-names>H.M.</given-names></name></person-group><article-title>The genotype-tissue expression (GTEx) project</article-title><source>Biopreserv. Biobanking</source><volume>13</volume><year>2015</year><fpage>307</fpage><lpage>308</lpage></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Borisov</surname><given-names>N.</given-names></name><name><surname>Shabalina</surname><given-names>I.</given-names></name><name><surname>Tkachev</surname><given-names>V.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Garazha</surname><given-names>A.</given-names></name><name><surname>Pulin</surname><given-names>A.</given-names></name><name><surname>Eremin</surname><given-names>I.I.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name></person-group><article-title>Shambhala: a platform-agnostic data harmonizer for gene expression data</article-title><source>BMC Bioinf.</source><volume>20</volume><year>2019</year><fpage>66</fpage></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Borisov</surname><given-names>N.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name></person-group><article-title>New paradigm of machine learning (ML) in personalized oncology: data trimming for squeezing more biomarkers from clinical datasets</article-title><source>Front. Oncol.</source><volume>9</volume><year>2019</year><fpage>658</fpage><pub-id pub-id-type="pmid">31380288</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Borisov</surname><given-names>N.</given-names></name><name><surname>Tkachev</surname><given-names>V.</given-names></name><name><surname>Suntsova</surname><given-names>M.</given-names></name><name><surname>Kovalchuk</surname><given-names>O.</given-names></name><name><surname>Zhavoronkov</surname><given-names>A.</given-names></name><name><surname>Muchnik</surname><given-names>I.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name></person-group><article-title>A&#x000a0;method of gene expression data transfer from cell lines to cancer patients for machine-learning prediction of drug efficiency</article-title><source>Cell Cycle</source><volume>17</volume><year>2018</year><fpage>486</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">29251172</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Tkachev</surname><given-names>V.</given-names></name><name><surname>Sorokin</surname><given-names>M.</given-names></name><name><surname>Mescheryakov</surname><given-names>A.</given-names></name><name><surname>Simonov</surname><given-names>A.</given-names></name><name><surname>Garazha</surname><given-names>A.</given-names></name><name><surname>Buzdin</surname><given-names>A.</given-names></name><name><surname>Muchnik</surname><given-names>I.</given-names></name><name><surname>Borisov</surname><given-names>N.</given-names></name></person-group><article-title>FLOating-window projective separator (FloWPS): a data trimming tool for support vector machines (svm) to improve robustness of the classifier</article-title><source>Front. Genet.</source><volume>9</volume><year>2018</year><fpage>717</fpage><pub-id pub-id-type="pmid">30697229</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A.</given-names></name><name><surname>Davis</surname><given-names>C.A.</given-names></name><name><surname>Schlesinger</surname><given-names>F.</given-names></name><name><surname>Drenkow</surname><given-names>J.</given-names></name><name><surname>Zaleski</surname><given-names>C.</given-names></name><name><surname>Jha</surname><given-names>S.</given-names></name><name><surname>Batut</surname><given-names>P.</given-names></name><name><surname>Chaisson</surname><given-names>M.</given-names></name><name><surname>Gingeras</surname><given-names>T.R.</given-names></name></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><year>2013</year><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>B.</given-names></name><name><surname>Braschi</surname><given-names>B.</given-names></name><name><surname>Gray</surname><given-names>K.A.</given-names></name><name><surname>Seal</surname><given-names>R.L.</given-names></name><name><surname>Tweedie</surname><given-names>S.</given-names></name><name><surname>Bruford</surname><given-names>E.A.</given-names></name></person-group><article-title>Genenames.org: the HGNC and VGNC resources in 2017</article-title><source>Nucleic Acids Res.</source><volume>45</volume><year>2017</year><fpage>D619</fpage><lpage>D625</lpage><pub-id pub-id-type="pmid">27799471</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Titov</surname><given-names>S.E.</given-names></name><name><surname>Ivanov</surname><given-names>M.K.</given-names></name><name><surname>V Karpinskaya</surname><given-names>E.</given-names></name><name><surname>V Tsivlikova</surname><given-names>E.</given-names></name><name><surname>Shevchenko</surname><given-names>S.P.</given-names></name><name><surname>Veryaskina</surname><given-names>Y.A.</given-names></name><name><surname>Akhmerova</surname><given-names>L.G.</given-names></name><name><surname>Poloz</surname><given-names>T.L.</given-names></name><name><surname>Klimova</surname><given-names>O.A.</given-names></name><name><surname>Gulyaeva</surname><given-names>L.F.</given-names></name><name><surname>Zhimulev</surname><given-names>I.F.</given-names></name><name><surname>Kolesnikov</surname><given-names>N.N.</given-names></name></person-group><article-title>miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors</article-title><source>BMC Canc.</source><volume>16</volume><year>2016</year><fpage>201</fpage></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>S.-K.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Jee</surname><given-names>H.-G.</given-names></name><name><surname>Kim</surname><given-names>B.-A.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Song</surname><given-names>Y.S.</given-names></name><name><surname>Cho</surname><given-names>S.W.</given-names></name><name><surname>Won</surname><given-names>J.-K.</given-names></name><name><surname>Shin</surname><given-names>J.-Y.</given-names></name><name><surname>Park</surname><given-names>D.J.</given-names></name><name><surname>Kim</surname><given-names>J.-I.</given-names></name><name><surname>Lee</surname><given-names>K.E.</given-names></name><name><surname>Park</surname><given-names>Y.J.</given-names></name><name><surname>Seo</surname><given-names>J.-S.</given-names></name></person-group><article-title>Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers</article-title><source>PLoS Genet.</source><volume>12</volume><year>2016</year><object-id pub-id-type="publisher-id">e1006239</object-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>S.-K.</given-names></name><name><surname>Song</surname><given-names>Y.S.</given-names></name><name><surname>Lee</surname><given-names>E.K.</given-names></name><name><surname>Hwang</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>H.H.</given-names></name><name><surname>Jung</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>Y.A.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Cho</surname><given-names>S.W.</given-names></name><name><surname>Won</surname><given-names>J.-K.</given-names></name><name><surname>Chung</surname><given-names>E.-J.</given-names></name><name><surname>Shin</surname><given-names>J.-Y.</given-names></name><name><surname>Lee</surname><given-names>K.E.</given-names></name><name><surname>Kim</surname><given-names>J.-I.</given-names></name><name><surname>Park</surname><given-names>Y.J.</given-names></name><name><surname>Seo</surname><given-names>J.-S.</given-names></name></person-group><article-title>Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer</article-title><source>Nat. Commun.</source><volume>10</volume><year>2019</year><fpage>2764</fpage><pub-id pub-id-type="pmid">31235699</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>N.J.</given-names></name><name><surname>Oberti</surname><given-names>M.</given-names></name><name><surname>Thangudu</surname><given-names>R.R.</given-names></name><name><surname>Cai</surname><given-names>S.</given-names></name><name><surname>McGarvey</surname><given-names>P.B.</given-names></name><name><surname>Jacob</surname><given-names>S.</given-names></name><name><surname>Madhavan</surname><given-names>S.</given-names></name><name><surname>Ketchum</surname><given-names>K.A.</given-names></name></person-group><article-title>The CPTAC data portal: a resource for cancer proteomics research</article-title><source>J.&#x000a0;Proteome Res.</source><volume>14</volume><year>2015</year><fpage>2707</fpage><lpage>2713</lpage><pub-id pub-id-type="pmid">25873244</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Aliper</surname><given-names>A.M.</given-names></name><name><surname>Korzinkin</surname><given-names>M.B.</given-names></name><name><surname>Kuzmina</surname><given-names>N.B.</given-names></name><name><surname>Zenin</surname><given-names>A.A.</given-names></name><name><surname>Venkova</surname><given-names>L.S.</given-names></name><name><surname>Smirnov</surname><given-names>P.Y.</given-names></name><name><surname>Zhavoronkov</surname><given-names>A.A.</given-names></name><name><surname>Buzdin</surname><given-names>A.A.</given-names></name><name><surname>Borisov</surname><given-names>N.M.</given-names></name></person-group><article-title>Mathematical justification of expression-based pathway activation scoring (PAS)</article-title><source>Methods Mol. Biol.</source><volume>1613</volume><year>2017</year><fpage>31</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">28849557</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P.</given-names></name><name><surname>Markiel</surname><given-names>A.</given-names></name><name><surname>Ozier</surname><given-names>O.</given-names></name><name><surname>Baliga</surname><given-names>N.S.</given-names></name><name><surname>Wang</surname><given-names>J.T.</given-names></name><name><surname>Ramage</surname><given-names>D.</given-names></name><name><surname>Amin</surname><given-names>N.</given-names></name><name><surname>Schwikowski</surname><given-names>B.</given-names></name><name><surname>Ideker</surname><given-names>T.</given-names></name></person-group><article-title>Cytoscape: a software Environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res.</source><volume>13</volume><year>2003</year><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0455">The following is the supplementary data related to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplementary_file 1.xlsx</title><p>Clinical annotation, mRNA sequencing file IDs and QC RIN scores of all patients analyzed in this study.</p></caption><media xlink:href="mmc1.xlsx"><alt-text>Supplementary_file 1.xlsx</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Supplementary_file 2.xlsx</title><p>STAR alignment and MAGIC quality control statistics of mRNA sequencing data obtained in this study.</p></caption><media xlink:href="mmc2.xlsx"><alt-text>Supplementary_file 2.xlsx</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc3"><caption><title>Supplementary_file 3.xlsx</title><p>Statistical parameters for differential expression of <italic>SERPINA1</italic>, <italic>LAMB3</italic>, <italic>TACSTD2, CPQ, TFF3, ACVRL1, PLVAP</italic> genes.</p></caption><media xlink:href="mmc3.xlsx"><alt-text>Supplementary_file 3.xlsx</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc4"><caption><title>Supplementary_file 4.xlsx</title><p>Alterations of pathway activation levels for 38 DNA repair pathways in differential comparisons of follicular adenoma (FA), follicular cancer (FC), papillary cancer (PC) and normal tissues (ANTE, GTEX and TCGA databases), and statistic characteristics of compared groups.</p></caption><media xlink:href="mmc4.xlsx"><alt-text>Supplementary_file 4.xlsx</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc5"><caption><title>Supplementary_file 5.xlsx</title><p>Node and gene characteristics for reconstructed pathways.</p></caption><media xlink:href="mmc5.xlsx"><alt-text>Supplementary_file 5.xlsx</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc6"><caption><title>Supplementary_file 6.xlsx</title><p>PAL values for all thyroid tissue samples investigated.</p></caption><media xlink:href="mmc6.xlsx"><alt-text>Supplementary_file 6.xlsx</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc7"><caption><title>Supplementary_file 7.xlsx</title><p>Alterations of pathway activation levels for 38 DNA repair pathways(dataset PRJEB11591) in differential comparisons of follicular adenoma (FA), follicular cancer (FC), follicular variant of papillary cancer (FV), classical variant of papillary cancer (PC) and adjacent normal tissues.</p></caption><media xlink:href="mmc7.xlsx"><alt-text>Supplementary_file 7.xlsx</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc8"><caption><title>Supplementary_file 8.xlsx</title><p>List of 871 differential genes between radioiodine resistance (RAIR) tumor samples and other thyroid cancers.</p></caption><media xlink:href="mmc8.xlsx"><alt-text>Supplementary_file 8.xlsx</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc9"><caption><title>Supplementary_file 9.xlsx</title><p>Gene contribution coefficients in the first two principal components according to Figure&#x000a0;19C.</p></caption><media xlink:href="mmc9.xlsx"><alt-text>Supplementary_file 9.xlsx</alt-text></media></supplementary-material></p></sec></back></article>